



Council of State and
Territorial Epidemiologists



CDC-CSTE Intergovernmental Data Release Guidelines Working Group (DRGWG) Report:

CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data

This report contains guidelines for implementing the *CDC/ATSDR Policy on Releasing and Sharing Data*, pertaining to the re-release of State data

drgwg report ver 6-2.doc

Table of Contents

i. Preface	4
1. Background and Purpose	4
2. Overview of Federal Laws Governing Data Release.....	6
3. What type of data do the CDC-ATSDR-CSTE Data Release Guidelines apply to?	13
4. The CDC-ATSDR-CSTE Data Release Guidelines for Re-Release of State Data.	17
A. All Re-Releases of State Data.....	19
Guideline 1: Privacy Officer.....	19
Guideline 2: Training.....	19
Guideline 3: Requirements imposed by States	20
Guideline 4: Potential Identifiers	23
Guideline 5: Aggregate data values	27
Guideline 6: Number of records, number of fields	28
Guideline 7: Numerator rules for data aggregation or suppression	29
Guideline 8: Denominator rules for data aggregation or suppression	33
Guideline 9: Data distortion.....	36
Guideline 10. Data set classification and access.....	37
Guideline 11: Log of data releases.....	40
B. Re-release of State Data as Public-Use Data	42
Guideline 12: Public-Use Without Restrictions.....	42
Guideline 13: Public Release Disclosure Statement.....	43
Guideline 14: Provisional data re-releases, for public use.....	45
C. Re-release of Data as Restricted-Access Data	46
Guideline 15: Authentication.....	46
Guideline 16: All requestors wanting to use restricted-access data are required to sign a DSA.	47
Guideline 17: Requirements for a Standard DSA for restricted-access data	48
Guideline 18: Required Addendum to the Standard DSA when a Data Requestor Plans to Link Restricted-Access Data to Other Data	52
Guideline 19: Required Addendum to the Standard DSA when a Data Requestor Plans Further Releases of Data to Other Parties, from Restricted-Access Data	54
Guideline 20: DSA compliance monitoring	56
Guideline 21: Provisional data re-releases, for restricted-access.....	57
Guideline 22: Emergency requests for data	58
5. Comments Regarding Adoption of the CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data	59
5.1 Proposed deadline for CDC's implementation of the Guidelines.....	60
5.2 Development of curricula for "special training".....	60
5.3 Development of a data set inventory to facilitate disclosure risk assessment ...	61
5.4 Current standards for de-identifying data sets and performing disclosure review assessment.....	62
5.5 Development of instructions data stewards can use to create PUDS for data re-releases, including FOIA requests.	63

5.6 Evaluations to assess whether a breach of confidentiality has occurred	64
5.7 Establish a CDC Intranet site where materials referenced in this report, from various web sites, are archived.	64
5.8 Feedback to CSTE regarding CDC’s implementation of the Guidelines	65
6. DRGWG Members	65
7. Acknowledgements:.....	66
8. Glossary	68
9. Appendices.....	72
Appendix A: History leading up to the establishment of the CDC-CSTE Intergovernmental Data Release Guidelines Working Group	72
Appendix B: Overview of the Freedom of Information Act, the Privacy Act, Confidentiality Assurances (308(d)), and Certificates of Confidentiality (301(d)).....	74
10. Supplemental Reading List.....	81
11. References.....	84

i. Preface

This report contains guidelines for implementing the CDC/ATSDR Policy on Releasing and Sharing Data pertaining to CDC's re-release of State data. Section 3 of this report describes the characteristics of CDC data systems that are considered in- and out-of-scope for this report, and includes some examples of in- and out-of-scope CDC data systems. Section 4 contains the actual guidelines. Each guideline represents a "minimum standard" for CDC and ATSDR Programs to address when developing their program-specific data release procedures for re-release of state-based data. Most guidelines are accompanied by a best practices statement, reflecting applicable references, resources, or selected examples of practices by CDC Programs or other Federal or state programs that appear to be consistent with the guidelines. The best practices statement is meant to be descriptive rather than prescriptive. In other words, it is being left to the discretion of each Center, Institute, or Office (CIO) and their respective Programs to consider for themselves whether it is appropriate to implement the listed best practice element or implement another approach to meet the intent of the guideline element.*

While the guidelines were developed for CDC data systems having specific characteristics, it is possible that the guidelines overall or specific guidelines may be applicable to other CDC data systems. However, this determination is left to the judgment of the CDC CIOs and their respective Programs.

Section 5 contains comments to help facilitate CDC's adoption of the guidelines. These comments list issues and ideas that may merit more discussion and consideration within CDC.

1. Background and Purpose

States⁺ have a long-standing history of voluntarily reporting individually identifiable data to CDC on incident conditions or diseases that are of public health importance¹. Recent developments in telecommunications and computerization have greatly enhanced public health's ability to compile and share data. While the electronic exchange and accumulation of data on individual cases promises public health benefits, it has the potential to threaten individual privacy. The challenge is to balance the need for data protection with another competing interest of public health—the need to share data

* Throughout this document, CDC should be understood to refer to both CDC and ATSDR.

⁺ Throughout this document, "States" should be understood to refer to both U.S. States and Territories.

that was collected in the interest of public health as broadly as possible, with appropriate protections, with public health practitioners and researchers conducting studies that have the potential to benefit public health. If such a balance is not achieved, data withholding by data providers for purposes of data protection may occur².

The U.S. State and Territorial Health Agencies operate within the authority of state-specific laws and regulations that control the collection and protection of individually identifiable data. Therefore, States are ultimately responsible for confidentiality protections, regardless of whether the data reside temporarily with a data steward such as CDC, or reside within their own agencies.

Since the mid-1980s, the CDC and Council of State and Territorial Epidemiologists (CSTE) have been engaged in extensive discussions over issues related to re-release by CDC of data released by states to CDC. Appendix A describes relevant events leading up to the establishment of the CDC-CSTE Intergovernmental Data Release Guidelines Working Group (DRGWG).

CDC has a responsibility to know how CDC programs are currently protecting the confidentiality of the state-based data they have been entrusted with and to communicate this information to CSTE. In addition, CDC and CSTE have a shared responsibility to consider the feasibility of developing guidelines for CDC programs that are consistent with state laws, regulations, and policies protecting confidentiality and that reflect state-of-the-art or best practices^{3,4,5,6}. The development of the *CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data* is intended to augment current CDC policies such as *The CDC Staff Manual on Confidentiality*⁷ and the *NCHS Staff Manual on Confidentiality*⁸.

The Excellence in Science sub-committee on data release and data sharing has been charged with developing a CDC/ATSDR policy on releasing and sharing data that covers data reported to CDC by States and other types of data. The *CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data* represent implementation procedures for applying the new *CDC/ATSDR Policy on Releasing and Sharing Data*⁹ as it relates to data provided by State and Territorial Health Agencies.

The DRGWG is charged with developing recommendations that will represent CDC-wide guiding principles (minimum standards) for the re-release of data by CDC, for data that were previously held by states and may be subsequently re-released by CDC. The DRGWG periodically receives input from CDC program staff who express the importance and need for CDC programs to have not only clear policy guidance on data release and data sharing, but also minimum standard implementation guidelines, aimed at facilitating implementation of the policy within CDC. The guidelines contained within this report should be used by CDC programs when developing their program-specific data re-release procedures.

2. Overview of Federal Laws Governing Data Release

CDC's practices and policies regarding data release are based on the framework of Federal Laws governing the maintenance and public disclosure of federal records, the protection of key public priorities such as privacy, proprietary information, and national security, and obligations arising out of litigation or other compulsory processes. The purpose of this section is to provide an overview of the major Federal Laws that may

affect the release of State data or that may compel disclosure of State data. The applicability and implications of these laws will vary depending on the nature of the data and other circumstances. These variations will not be analyzed in detail here. Questions by data stewards about the applicability of legal requirements should be directed to appropriate legal counsel.

Data collected by CDC, including data collected by States and sent to CDC, becomes a federal record once received by CDC, and is subject to Federal laws and rules governing data release and Federal records retention laws. These include, but are not limited to, the Federal Records Act, the Freedom of Information Act, the Privacy Act, Confidentiality Assurances, and Certificates of Confidentiality.

The Federal Records Act (44 U.S.C. Chapter 33, 36 CFR Chapter 12, Subchapter B, Records Management) prescribes how and for how long federal records are to be maintained, when they may be destroyed, and when they may or must be archived. In general, original data received by CDC in the form of paper or electronic data are kept for a standard period of ten years, and then archived or destroyed in accordance with the approved CDC Records Control Schedule (Item 2-47, Research Working Papers B-231). CDC's retention of this information does not negate the requirement that organizations (e.g., State agencies) follow records retention guidelines required under law and by local and state governments. In addition, requirements imposed by states requiring CDC to destroy or return data and records may conflict with CDC's record retention obligations.

The Freedom of Information Act (FOIA) (URL: <http://www.cdc.gov/od/foia/foi.htm>) generally provides that, upon written request from any person, a Federal agency must release any agency record unless that record falls within one of nine exemptions. Since, as stated above, State based data becomes a Federal record in CDC's possession, such records are subject to disclosure in response to a FOIA request. However, several of these FOIA exemptions may be available to protect some aspects of State data from public disclosures in response to a FOIA request (see Table 1 and Appendix B).

The Privacy Act (5 U.S.C. 552a) prohibits agency disclosure of any record maintained in a federal system of records when the primary method by which the data will be retrieved is by name, social security number, or other identifying particular, such as thumb print, except pursuant to a written request, or with the prior written consent of, the individual to whom the record pertains. The creation of a federal system of records is announced in the Federal Register. While the Privacy Act is generally protective, it contains several exceptions to the Privacy Act which permit disclosure without a subject's consent, including disclosure of the record for a routine use. A routine use is a disclosure which is compatible with the purpose for which the record was collected, and which is included in the system notice. A complete list of exceptions is found within Title 5 U.S.C. 552(a) (see Appendix B).

In addition to the Privacy Act, which contains criminal penalties for the unauthorized disclosure of protected information, the *Trade Secrets Act* (Table 1) makes

it unlawful for any officer or employee of the United States or of any Federal department or agency to publish, divulge, disclose, or make known in any manner not authorized by law any information gained through the course of federal employment that concerns or relates to “trade secrets, processes, operations, style of work, or apparatus, or to the identity, confidential statistical data, amount or source of any income, profits, or losses, or expenditures of any person, firm, partnership, corporation, or association...”

Information acquired through the course of official duties, though an investigation or examination, or seen in a document is covered by the Trade Secrets Act. Some types of data CDC receives from States may fall under this act, making the unauthorized disclosure potentially a criminal offense. Under the Trade Secrets Act, a person “...shall be fined not more than \$1,000, or imprisoned not more than one year, or both; and shall be removed from office or employment.” Under the Privacy Act of 1974, Subsection 552a(i) (1), a person who willfully discloses information to another person who isn’t entitled to receive it “...shall be guilty of a misdemeanor and fined not more than \$5,000.” The “Related Statutory Authorities” section of the Standards of Ethical Conduct for Employees of the Executive Branch (5 CFR 2635.902; see http://www.usoge.gov/pages/laws_regs_fedreg_stats/oge_regs/5cfr2635.html) cites the prohibition against disclosure of proprietary information and certain other information of a confidential nature which is contained in the Trade Secrets Act.

Special Confidentiality Protections. A limited number of CDC projects that collect highly sensitive identifiable information have received approval for formal confidentiality protection under Sections 301(d) or 308(d) of the Public Health Service

(PHS) Act (42 U.S.C. Sections 241(d) and 242(m)(d) (see Appendix B). In addition, data collected by the National Center for Health Statistics (NCHS) is covered by section 308(d). Data collected under a project with a 308(d) assurance of confidentiality may not be released in identifiable form without the consent of the individual or entity that supplied the information. CDC has historically been rigorous in its approval process for the discretionary use of this authority in order to prevent misuse of the protections as a mechanism for refusing to share data.

Data collected under a 301(d) Certificate of Confidentiality may be protected from disclosure to persons not connected to the research. In addition, such researchers “...may not be compelled in any Federal, State, or local civil criminal, administrative, legislative, or other proceedings to identify such individuals.”

National Security. In some circumstances, State data disclosed to CDC may be relevant to national security. CDC may need to evaluate any risk to national security posed by a release of this data. CDC maintains classified information in accordance with Executive Order 12958. (See CDC Manual Guide No. CDC-5: Information Resources Management—Policy on Classified Material, rev 2002.) The Department of Health and Human Services (DHHS) was recently given authority to classify information in accordance with this order under 66 F.R. 64347 (2001). Determination of classification is made by the Secretary, DHHS. The need to protect sensitive but **unclassified** information from inappropriate disclosure is carefully balanced, on a case by case basis, with the benefits that result from the open and efficient exchange of scientific, technical,

and like information. Release of such information to the public is made in accordance with FOIA.

Legal Proceedings. In some instances, data collected by CDC, including data collected by States and sent to CDC, may be implicated in some type of lawsuit or administrative proceeding. The disclosure of such data may be sought through voluntary disclosure or compulsory process. Generally, CDC utilizes available legal mechanisms to protect the confidentiality of identifiable data, and to protect other public interests described previously. Generally, CDC has been successful in such instances. (see for example, Farnsworth v. Proctor and Gamble Company, et al, 101 F.R.D. 355 (U.S. Dist. 1984). However, it is important to keep in mind that the ability to protect confidential or identifiable information in litigation or other legal proceedings depends on a variety of factors such as whether the data has special confidentiality protection, the type of court or forum, whether it is a Federal or State proceeding, whether the United States is a party, and the particular laws at issue.

The *human subjects Common Rule* (Table 1) applies to all applications and proposals for research involving human subjects to be conducted, supported, or subject to regulation by a federal department or agency. One of the many requirements of the Common Rule includes the provision, when appropriate, for the privacy of subjects to be protected.

Table 1. Federal Laws and Rules Applicable to CDC's Release of Data

- I. Federal Records Act
44 U.S.C. Chapter 33, 36 CFR Chapter 12, Subchapter B, Records Management
 - II. Freedom of Information Act (FOIA)
5 U.S.C. 552
<http://www.usdoj.gov/foia/foiastat.htm>
<http://www.cdc.gov/od/foia/foi.htm>
http://www.usdoj.gov/foia/04_3.html
 - III. Privacy Act
5 U.S.C. 552a
<http://www.usdoj.gov/foia/privstat.htm>
 - IV. Trade Secrets Act
18 U.S.C. Section 1905
 - V. Standards of Ethical Conduct for Employees of the Executive Branch
5 CFR 2635.902
http://www.usoge.gov/pages/laws_regs_fedreg_stats/oge_regs/5cfr2635.html
 - VI. Special Confidentiality Protections

Assurance of Confidentiality
Section 308(d) of the Public Health Service Act
42 U.S.C. 242(m)(d)

Certificate of Confidentiality
Section 301(d) of the Public Health Service Act
42 U.S.C. 241(d)
 - VII. DHHS Authority to Classify National Security
66 F.R. 64347 (2001)
 - VIII. Human Subjects Common Rule
45 C.F.R. Part 46, Section 46.111
<http://ohrp.osophs.dhhs.gov/humansubjects/guidance/45cfr46.htm#46.111>
-

3. What type of data do the CDC-ATSDR-CSTE Data Release Guidelines apply to?

The *CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data* apply to the policies and practices CDC programs establish for the re-release of state-based data. State-based data are defined, in this report, as population-based data intended to represent a complete count of cases or a statistical sample of all cases in a given population, that are collected by U.S. State and Territorial Health Agencies related to the health or exposure status (and possibly also vital status) of individual U.S. residents, which fall under state legal authority for collection and protection of privacy and confidentiality. The Guidelines also apply to unweighted microdata^{10,11} (individual person records) from sample surveys administered by State Health Agencies which send CDC data containing personal identifiers or information about survey respondents that could potentially be used to identify survey respondents. Furthermore, these data release guidelines apply to state-based surveillance and information systems about events (as opposed to people) but only if data about individuals are also collected in association with the event under investigation.

Data from Indian Tribal nations that comes to CDC **indirectly** through State Health Agencies are covered by the Guidelines in this report because these data are being directly reported to CDC under the authority of the State Health Agency. For CDC public health surveillance systems, such as the Vaccine Adverse Events Reporting System, which are comprised of data from State Health Agencies and other data sources,

one data release procedure should be developed and that procedure should not be in conflict with the data release guidelines for State data. Vital statistics data may be exempt from the Guidelines contained in this report because of the longstanding history of data agreements that have been in place between the State Vital Registrars and the National Center for Health Statistics, through a contract negotiated by the National Association for Public Health Statistics and Information Systems. [COMMENT: The Excellence in Science sub-committee on data release and sharing has been asked to help resolve the issue about whether vital statistics data should be covered by the Guidelines in this report. A meeting to help resolve this issue is being planned.] Examples of data that the *CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data* apply to include, but are not limited to the following:

CIO	Program
ATSDR	Hazardous Substances Emergency Events Surveillance
EPO	Medical Examiner and Coroner Information Sharing Program
EPO	National Notifiable Diseases Surveillance System
NCCDPHP	National Program of Cancer Registries, Cancer Surveillance System
NCCDPHP	Pregnancy Risk Assessment Monitoring System
NCEH	Childhood Blood-lead Poisoning Surveillance System
NCHS	Vital Statistics Birth and Death Records [Scope issue under discussion]
NCHSTP	HIV and AIDS Reporting System
NCHSTP	Tuberculosis Information Management System
NCHSTP	Sexually Transmitted Disease Management Information System
NCIPC	National Violent Death Reporting System

NIP	Vaccine Adverse Events Reporting System
NIOSH	Sentinel Event Notification Systems for Occupational Risks
NIOSH	Adult Blood Lead Epidemiology and Surveillance Program

Data that are not specifically covered by the CDC-ATSDR-CSTE data release guidelines include, but are not limited to, the following: a) individually identifiable data that are not collected under U.S. State health agency authority, such as data that CDC collects directly, data that U.S. cities collect and report to CDC, and data that are reported directly to CDC by Indian Tribal nations (these Guidelines cannot apply to Indian Tribal nations because Federal and State governments recognize the sovereignty of Indian Tribal nations); b) data collected specifically for research or an outbreak investigation; c) data that are not individually identifiable or potentially identifiable; d) data systems that use public-use data compiled from another data system considered to be the primary data system; and e) possibly vital statistics birth and death data. Examples of data systems that are not covered by the CDC-ATSDR-CSTE data release guidelines include, but are not limited to the following:

CIO	Program	Reason the Guidelines Do Not Apply
EPO	122 Cities Mortality Reporting System	Only summary counts (aggregate data) are reported to CDC; thus, CDC doesn't receive individually identifiable data. In addition, these data are collected and reported by selected U.S. cities, not the state health agency.
NCHS	Vital Statistics Birth and Death Records	These data are already governed by NCHS data use agreements with States.

		[Scope issue under discussion]
NCIPC	National Public Health Surveillance System Injury Indicators Report	These data are a compilation of data reported from other data systems.
NIOSH	National Surveillance System for Pneumoconiosis Mortality	This system is based on public-use data from NCHS mortality files.

4. The CDC-ATSDR-CSTE Data Release Guidelines for Re-Release of State Data.

This section describes the 22 guideline elements (the “Guidelines”) that collectively constitute the *CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data*. Each guideline represents a “minimum standard” for CDC and ATSDR Programs to address when developing their program-specific data release procedures for re-release of state-based data. The guidelines are grouped into three main categories: (1) guidelines that apply to all re-releases of data, (2) guidelines that apply to re-releases of State data as public-use data, and (3) guidelines that apply to the re-release of data as restricted-access data. Best practices statements accompany most of the guidelines. The best practices statements reflect applicable references and resources or selected examples of practices by CDC programs or other Federal or state programs that appear to be consistent with the guidelines. On occasion, more than one best practices standard is shown because they may represent viable alternative options for a specific CDC program unit. The best practices statements differ from the guidelines, in that the best practices statements are not minimum standards, but rather a listing of approaches that may merit more discussion and consideration within CDC. The best practices statements are meant to be descriptive rather than prescriptive. In other words, it is being left to the discretion of each CIO and their respective Programs to consider for themselves, whether it is appropriate to implement the listed best practices statements or implement another approach to meet the intent of the guideline.

Many of the guidelines listed below are not specific to State data, while some are (e.g., Guideline 3: Requirements imposed by States). While the guidelines were developed for CDC data systems having specific characteristics, it is possible that the guidelines overall or specific guidelines may be applicable to other CDC data systems. The determination of which guidelines may apply to other CDC data systems (or for that matter, to State data systems) is left to the judgment of the CDC CIOs and their respective Programs.

The guidelines below that apply to the re-release of restricted-access data using Data Sharing Agreements (see Section C of this section), do not apply to re-release of restricted-access data through CDC-controlled data centers or by licensing appropriate non-CDC researchers to use certain data. At the time this report was developed, only NCHS was re-releasing data through research data centers and no CIOs were re-releasing data through licensing agreements. Hence, until CDC implements a process for instituting these alternative mechanisms for data re-release more broadly within CDC, it was premature for this report to address the procedures needed for these alternative mechanisms for data re-release. In the future, CDC and CSTE will need to develop additional implementation policies and procedures for data re-released through these mechanisms. For information about the NCHS Research Data Center, refer to URL <http://www.cdc.gov/nchs/r&d/rdc.htm>. Additional information about data centers^{5,12} (controlled sites for accessing data) and data licensing^{5,13} can be found elsewhere.

All the guidelines below apply to data released in any format (including tabular data [precalculated tables], microdata, on-line query systems or other formats), unless the guideline states that it applies only to data released in one or more specific formats.

A. All Re-Releases of State Data

Guideline 1: Privacy Officer

Each CDC program unit that re-releases state-based data will designate a privacy officer to clear all proposed releases of state data, including data re-releases made within the provisions of an inter-agency Memorandum of Understanding (MOU). Potential confidentiality breaches should be reported to the Privacy Officer[§]. The Privacy Officer, in turn, should report this information to the CIO data-release review board[†].

► **Best Practices for Guideline 1:** The designated program unit data steward can act as the privacy officer. Oversight for the privacy officer can be provided by a CIO data-release review board, which might report to the CIO Associate Director of Science (ADS), and might include the CIO Information Resources Manager (IRM) and relevant data stewards (see *CDC/ATSDR Policy on Releasing and Sharing Data*⁹).

Guideline 2: Training

The CDC program unit that re-releases state-based data will ensure that staff responsible for data release will complete special training in confidentiality protection and disclosure

[§] The terms Privacy Officer and Confidentiality Officer are synonymous terms, for the purpose of this report.

[†] Throughout this document, the phrase “CIO data-release review board” also includes alternative oversight mechanisms that CIOs establish for data release.

risk assessment and control. *Note: Curricula for "special training" have yet to be determined, but Comment 5.2 (in Section 5 of this report) addresses the need for CDC to itself develop or for CDC to contract with others to develop training curricula.*

► **Best Practices for Guideline 2:** Training for staff involved in making decisions about data release at the time of first employment and annually thereafter, as a training refresher, is ideal. The supervisors of data release decision makers should also receive this training. Until CDC makes training available, a recent text will serve as a useful reference³. In addition, the Federal Committee on Statistical Methodology (FCSM) Confidentiality and Data Access Committee (CDAC) has developed a one-day short course, entitled "Privacy, Confidentiality and the Protection of Health Data - A Statistical Perspective," which is available through special request (see <<http://www.fcsm.gov/cdac/index.html>>).

Guideline 3: Requirements imposed by States

The CDC program unit that re-releases state-based data will comply with requirements imposed by States which release State data to CDC, insofar as possible, within the framework of the federal laws and regulations that are applicable (see Section 2 of this report for a summary of the Federal laws that apply to CDC's re-release of data). CDC expects that the State transmitting data to CDC will have cleared the release based upon

any applicable state policies, laws, and regulations that apply to their transfer of data to CDC.

The CDC program will provide state and territorial data providers with a statement describing the *CDC/ATSDR Policy on Releasing and Sharing Data*⁹ and the CDC Program's data release procedure, including the content and format of data to be released as either non-identifiable public-use data or identifiable/potentially identifiable restricted-access data. The CDC program will review and, if necessary, update the data release procedure statement periodically, and will notify states whenever a change in procedure is anticipated.

If the CDC Program's procedure for data re-release does not provide adequate protection to a given State's data, the CDC Program needs to work with the State to ensure an appropriate policy is developed. In order to tailor the CDC data re-release procedure to meet the requirements of one or more States, the CDC program will provide (if feasible) specific re-release options States can select from. These options could provide limited customization of the CDC data re-release procedure, in terms of specific issues, such as withholding the re-release of variables below a specified sub-state geographic level. While States have the option to refrain from providing data to CDC if CDC policy or practice provides less protection than State requirements, this should be a very rare occurrence that is only used as a last resort option by the State.

When the CDC program staff are initially planning to draft program-specific data re-release procedures, they should be in contact with States so they are aware of key issues that may have a bearing on preparation of the plan.

The CDC program should ensure that provisions of State requirements are followed by asking States to send a formal “statement of response” within a specified response period to the CDC program, indicating agreement or disagreement with the CDC program data re-release procedure, and responding to specific options for re-release, if the CDC program offered options. In the absence of a formal statement of response from a given State, CDC can assume the State is in agreement.

► Best Practices for Guideline 3: The CDC AIDS Program asked States to select the level of sub-state geographic detail that specific variables in the AIDS Public Information Data Set (PIDS) could be tabulated for, by pre-defining a select group of options they could select from, such as health-district level; county-level; MSAs with 100,000 or more people; MSAs with 500,000 or more people only, etc. This process enabled States to customize the AIDS data release procedures to meet the different requirements of the States.

Guideline 4: Potential Identifiers

The CDC program unit that re-releases state-based data will delete, as necessary, all information judged to be of potential use in making individuals to whom they pertain “identifiable” (see “individually identifiable data” in Glossary). Particular attention will be devoted to information that can lead directly to an individual or their family, such as:

- Name
- Street address
- Social Security Number
- Medical record number
- Telephone number

Other information is extremely useful in narrowing the possibilities that information may refer to a particular individual. Those providing low level geographic detail and precise timing of certain events are particularly important.

Geographic Information

- Zip code (9-, 5-, and even 3-digit)
- Census tract
- City/town
- County

Timing of events

- Exact date of birth (yr-mo-da)
- Exact date of event (yr-mo-da)

- Month and year of birth (yr-mo)
- Month and year of event (yr-mo)

Information for geography and timing of events, along with details concerning the following types of information can serve to further confirm individual identity:

- Occupation (e.g. 3- or higher digit codes)
- Education (e.g. single years)
- Race/ethnicity (e.g. Aleutian, Filipino v. Asian)
- Income (as a continuous, un-topcoded variable)
- Medical condition/diagnosis (e.g. detailed site specific cancers) and cause of death (e.g. 3 digit ICD code)

There could be other surveillance system-specific variables that may be used to help further confirm individual identity.

Prior to re-release, these items must be thoroughly reviewed for their potential for personal re-identification. *It is not the intent of these guidelines to imply that all of these fields must always be deleted.* Under appropriate conditions and with proper safeguards, such items may be released. It is not the intent of these guidelines to recommend a single strategy for the limitation of disclosure risk. It is recognized that both programmatic and statistical considerations may come into play in deciding appropriate protections for data

release. For example, an alternative to field (variable) deletion is data value recoding (see Guideline 5: Aggregate data values).

Prior re-releases of data should be considered in a cumulative fashion. As stated in the document *Identifiability in Microdata Files*²⁴ “Each of these files may be considered safe to release by themselves. However, there may be enough information in the two files combined to effect a re-identification.”

► Best Practices for Guideline 4:

Refer to the Federal Committee on Statistical Methodology’s *Statistical Working Paper #22: Report on Statistical Disclosure Limitation Methodology*¹⁹ for a description of common methods used to protect microdata and tabular data, available at URL:

<http://www.fcsm.gov/working-papers/wp22.html>. Additional guidance is available in the Federal Committee on Statistical Methodology’s Confidentiality and Data Access Committee Checklist on Disclosure Potential of Proposed Data Releases⁶ (URL: <http://www.fcsm.gov/committees/cdac/index.html>).

Additional guidance as well as bibliographical materials on statistical disclosure limitation methodology can be found at this website as well as that of the Committee on Privacy and Confidentiality of the American Statistical Association (URL: <http://users.erols.com/dewolf/pchome.htm>).

The Health Insurance Portability and Accountability Act²¹ (HIPAA) 2001 Privacy Rule's safe harbor method of de-identification (which requires covered entities to remove all of a list of 18 enumerated identifiers and have no actual knowledge that the information that remains could be used alone or in combination to identify an individual who is a subject of the information) is deemed inadequate protection for public health agencies to use for de-identifying data sets because public health agencies collect many more demographic variables than do covered entities. In addition, public health agencies are expected to have a much higher level of sophistication with regard to disclosure review than covered entities.

The HIPAA Privacy Rule de-identification standard that is consistent with this guideline requires "a person with appropriate knowledge and experience applying generally acceptable statistical and scientific principles and methods for rendering information not individually identifiable makes and documents a determination that there is a very small risk that the information could be used by others to identify a subject of the information."

The HIPAA Privacy Rule was modified in 2002. The 2002 modification to the HIPAA Privacy Rule permits release of data

that is not fully de-identified through a “limited data set,” as long as the data are governed by a data use agreement which provides sufficient privacy and confidentiality protection for the data. For the limited data set, all direct identifiers must be removed from the data file. However, dates such as birth date, date of death, and dates of admission or discharge could be released in the data file, but only if this information is needed for the purpose of the release. In addition, the limited data set may include 5-digit zip code or any other geographic subdivisions, such as State, country, city, precinct and their equivalent geocodes, except for street address. (See August 14, 2002 Federal Register Notice updating 45 CFR Parts 160 and 164 of the HIPAA Privacy Rule, at URL: <http://www.hhs.gov/ocr/hipaa/privrulepd.pdf>.)

The Privacy Rule clarifies standards for the creation of de-identified data sets and “limited data sets.” The limited data set concept is consistent with the concept of “restricted-access” data that is discussed in this report.

Guideline 5: Aggregate data values

The CDC program unit which re-releases state-based data, either as "microdata" files (e.g., data files or records on an individual person) or as tabular data, will recode fields as needed in order to aggregate data values. Common methods are:

- collapse into broad categories for continuous/interval data (e.g., age, date of occurrence)
- collapse into broader categories for ordinal data (e.g., location geography)
- grouping into broad categories for nominal data (e.g., diagnosis)
- truncation (e.g., name)
- top-coding or bottom-coding.

► Best Practices for Guideline 5: Refer to the Federal

Committee on Statistical Methodology's *Statistical Working Paper #22: Report on Statistical Disclosure Limitation Methodology*¹⁹ for a description of common methods used to protect microdata and tabular data, available at URL: <http://www.fcsm.gov/working-papers/wp22.html>.

Guideline 6: Number of records, number of fields

The CDC program unit which re-releases state-based data as “microdata” files will consider the applicability of other methods to protect microdata releases from disclosure risk. Common methods are:

- Include data from only a sample of the population;
- Limit the number of variables in the file. For example, consider releasing: (1) only those variables essential to analysis, and (2) limit the number of contextual or ecological variables--information that describes a geographic area, such as

where a case-patient resides--because this type of information can lead to the identification of that area.

► **Best Practices for Guideline 6:** Refer to the Federal Committee on Statistical Methodology's *Statistical Working Paper #22: Report on Statistical Disclosure Limitation Methodology*¹⁹ for a description of common methods used to protect microdata, available at URL: <http://www.fcsm.gov/working-papers/wp22.html>.

Guideline 7: Numerator rules for data aggregation or suppression

The CDC program unit which re-releases state-based data as tabular data or microdata will use numerator rules (cell size) to either

- guide selection of groupings of aggregated data values, or, if aggregation is insufficient
- suppress release of certain cells in a table.

There is no single numeric threshold for cell aggregation that is appropriate for all data in tabular or microdata format. Selection of an appropriate threshold level is guided by multiple factors, including:

- The sensitivity of the data (subject matter);
- The format of the data (e.g., whether the data are continuous or categorical);
- The level of detail in the data, especially the level of geographic detail;

- The likelihood that a specific record in a data base may represent a unique person in a small population;
- The population or subgroup denominator size as well as the numerator size.

► **Best Practices for Guideline 7:** The appropriate level of cell suppression may vary based on the geographic level of detail being presented. For example, at the national level, there may be no reason to suppress any data, but as the denominator size decreases, such as at the state, county, or smaller geographic level, cell suppression may need to be employed to prevent inadvertent re-identification of the person described in the data base.

The following are some examples of cell suppression rules (see also Healthy People 2010 Statistical Notes, Number 24, published by NCHS in July 2002, accessible at this URL:

<<http://www.cdc.gov/nchs/products/pubs/pubd/hp2k/statnt/30-21.htm> >:

The *CDC Staff Manual on Confidentiality* generally advises a minimum numerator cell size of “3” . Thus, numerator cell size counts of “1” or “2” are not generally advised, with some notable exceptions.

The *CDC Staff Manual* indicates the following exceptions to minimum numerator cell size rule of “3”:

- a) “It has been a longstanding tradition in the field of morbidity or mortality [and vital] statistics not to suppress small frequency cells in the tabulation and presentation of data. For example, it has been considered important to know that there were two deaths from rabies in Rio Arriba County, N. Mex., in a given year, or that there were only one infant death and two fetal deaths in Aitkin County, Minn. These types of exceptions to general CDC practices in other programs are followed because they have been accepted traditionally and because they rarely, if ever, reveal information about individuals that is not known socially.”
- b) “Tables may show simple *counts* of numbers of persons, even though the number in a cell is only ‘1’ or ‘2’ provided the classifying data are not judged to be sensitive in the context of the table...”

The Washington state guideline states “If the count of cases or events in a cell is less than three, the data analyst needs to consider whether a breach of confidentiality is likely. A count of no events in the cell is clearly no threat to confidentiality, but a count of one

or two events may be.” (See

<http://www.doh.wa.gov/Data/Guidelines/SmallNumbers.htm>.)

At the Agency for Healthcare Research and Quality (AHRQ) Healthcare Cost & Utilization Project (HCUP) interactive query website¹⁴, AHRQ suppresses “Values based on 30 or fewer discharges” from tabular results of State HCUP tables. (See <http://www.ahrq.gov/data/hcup/hcupnet.htm>.)

A rule which combines numerators and denominators will meet this standard, such as a rule that data are not released if the population is less than a certain size and the number of events in a cell is less than a certain size. For example, Missouri uses a complex combined rule¹⁵: “A table is not reported if a table cell subtracted from the number of total events of the same data file for the same characteristics yields a small number (less than 10).”

When primary cell suppression is used, it is generally accepted that: 1) complementary cell suppression will need to be employed to avoid back-calculation by subtraction, and 2) if tabular data are suppressed using automated algorithms on a large number of related tables, that procedures for post-suppression auditing should be employed. However, precise methods for automated

suppression and auditing, that are easily implemented, still need to be developed. Therefore, at this time, it is not possible to implement this “best practice,” but it should be considered for future implementation.

Guideline 8: Denominator rules for data aggregation or suppression

The CDC program unit which re-releases state-based data as tabular data or microdata will use denominator rules (population size) to either

- guide selection of groupings of aggregated data values, or, if aggregation is insufficient, or
- suppress release of certain cells in a table.

► **Best Practices for Guideline 8:** A rule which combines numerators and denominators will meet this standard, such as a rule that data are not released if the total population from which the data are drawn is less than a certain size (a size sufficiently large that no subcell of the variables contained in the data would be expected to be smaller than a certain size – an approach commonly used for microdata), one based upon the size of the denominator from which events are drawn in tabulated data, or one that addresses the relationship between the size of the numerator and the size of the denominator.

In considering the population size in tabulated data, guidelines employed by the Washington State Department of Health state that “Generally, tabular data based on denominators greater than 300 persons per cell present minimal risk for individual identification. ... Caution should be exercised by the analyst if the population size is between 100 and 300, and extreme caution is warranted when the population is less than 100.” (See <http://www.doh.wa.gov/Data/Guidelines/SmallNumbers.htm>.)

As indicated in Guideline 7 above, in the case of tabulated data Missouri focuses on the number of people in the population with the characteristic indicated in a given numerator. If the difference between the two exceeds a minimum number, this information would not be published. On the other hand, in this scheme a very small cell number could be published if the denominator were large enough. (See URL: <http://www.cdc.gov/epo/dphsi/AI/confiles/day1/Land1.ppt>).

With regard to *total* population size, the statistical literature contains a great deal of discussion of appropriate minimal sizes and there is clearly variation depending upon information content and special considerations. The most general statement is found in the Federal Committee on Statistical Methodology’s Statistical

Policy Working Paper 2 where it is stated “Geographic information must be restricted beyond the point where an individual user could be familiar with a significant proportion of the universe, but whether that point comes at 25,000, 250,000 or 1 million will depend on the detail in the file and other restrictions imposed.”

See <http://www.fcsn.gov/working-papers/sw2.html> p 28.

The Federal Committee on Statistical Methodology’s Confidentiality and Data Access Committee Checklist on Disclosure Potential of Proposed Data Releases⁶ calls for “a minimum of 100,000 persons in the sampled area ... [else] provide rationale.” (See

http://www.fcsn.gov/committees/cdac/checklist_799.doc.)

The NCHS version of this checklist contains the following language:

“ Generally one has to balance the level of survey detail against the level of geography. The greater the amount of detail, the more risk is entailed for lower levels of geography. Similarly, with very high levels of geography, greater detail may be made available.

General Rule: All geographic areas that are identified must have a minimum of 100,000 persons in the sampled area (according to latest Census or Census estimate).

Caution: *the figure of 100,000 is not without some risk. For certain target populations the members of which are be found infrequently in a population, a higher number may be desired.”*

Guideline 9: Data distortion

The CDC program unit which re-releases state-based data will refrain from distorting data (either altering data values or omitting records from the dataset) unless this approach is employed as a last resort and is absolutely necessary for the purpose of privacy protection.

► **Best Practices for Guideline 9:** Current methods of perturbative "statistical disclosure control" are not optimal. At the discretion of the CIO, when a data requestor plans to make public health recommendations based on analysis of altered data, the CDC program unit holding that data may offer to confirm the requestor's findings by performing a re-analysis on un-altered data. Alternatively, researchers should be provided the opportunity to have restricted-access under a data sharing agreement or conduct re-analysis themselves in a CDC-controlled research data center.

Guideline 10. Data set classification and access

Each program unit which re-releases state-based data will classify each data set, whether developed for "planned release" or created in response to a data request, as either a public-use data set (PUDS) or a "restricted-access" data set.

A PUDS is comprised of data that have been modified to the maximum extent needed to block breaches of confidentiality and prevent identity disclosure or disclosure of confidential information. There should be no restrictions on access to PUDS (see Guideline 12). However, a public release disclosure statement should accompany the PUDS (see Guideline 13).

Restricted-access data sets include either the full data set States provide to CDC for program planning and evaluation (including etiologic studies), or a version of the full dataset that has been partially or substantially modified to minimize the likelihood of breaches of confidentiality. States need to confirm, via the "statement of response" (see Guideline 3) whether they support re-release of their data as a restricted-access data file. As the name implies, access to these data are restricted as follows:

- For CDC and state and local public health employees, permission for use of restricted-access data sets will be limited to those employees having official programmatic duties requiring access to these data.
- For other data requestors, permission for use of restricted-access data will be based upon a review of the stated purpose of the data request (the stated purpose

of the data request should be consistent with the original purpose for data collection), an assessment of whether the requested data would be appropriate to use for the intended purpose, and the need for using restricted-access data versus another type of available data set (such as a PUDS).

CDC programs should develop a procedure describing the criteria for determining who can access non-PUDS (restricted-access) data and the party or parties within CDC who are responsible for making these decisions. Procedures for releasing restricted-access data include authenticating the requestor's identity (see Guideline 15) and the use of data sharing agreements (DSA) (see Guidelines 16-20).

► **Best Practices for Guideline 10:** *The CDC/ATSDR Policy on Releasing and Sharing Data* states: “CDC strives to have data release policies that are fair to all users, regardless of their organizational affiliation.”

The *NCHS Policy on Micro-data Dissemination*¹⁶ (URL: <http://www.cdc.gov/nchs/about/policy/policy.htm>) states: “No individual—at NCHS or elsewhere—may claim entitlement to obtain or access identifiable data collected by NCHS by virtue of his or her employment. Access to identifiable data is not determined solely by employment status, organizational affiliation, or financial commitment. More important are the need for identifiable data,

the use to which the data will be put, and the requestor's role and responsibility with respect to the data collection activity. Since any access to identifiable data poses risk, access to such data will be carefully evaluated and tracked after access is granted.”

The CDC/NCHSTP assurance of confidentiality for HIV/AIDS data states “No CDC HIV/AIDS surveillance or research information that could be used to identify any individual or institution on whom a record is maintained, either directly or indirectly, will be made available to anyone for non-public health purposes. In particular, such information will not be disclosed to the public; to family members; to parties involved in civil, criminal, or administrative litigation, or for commercial purposes; to agencies of the federal, state, or local government. Data will only be released to the public, to other components of CDC, or to agencies of the federal, state, or local government for public health purposes in accordance with the policies for data release established by the Council of State and Territorial Epidemiologists.”

The ‘minimum necessary’ standard provision in the HIPAA Privacy Rule indicates that a “covered entity must make reasonable efforts to limit protected health information to the minimum

necessary to accomplish the intended purpose of the use, disclosure, or request.” Applying the intent of this standard to CDC data re-release procedures, only the minimum necessary data elements that can be justified by the data requestor to accomplish the proposed analysis should be re-released to data requestors, because additional variables may increase the disclosure risk potential of the data unnecessarily.

Guideline 11: Log of data releases

The CDC program unit which re-releases state-based data will maintain a log of releases.

► **Best Practices for Guideline 11:** A computerized log of releases allows for simplified examination of audit trails.

For PUDS data, the log of releases represents an inventory of the different PUDS data sets CDC has re-released. Ideally, such an inventory would be posted on the Internet, include all state-based PUDS public health surveillance data re-released by CDC, and be formatted so it can be queried by users. While the inventory is useful to inform interested parties as to the existence of these data sets, its primary function within CDC is to remind the CDC program that a potential exists for data users to want to combine related data sets in order to access more information than just a

single data set would provide. Thus, the inventory should remind CDC programs of the need to perform disclosure risk assessment within the context of all previous re-released related data sets.

Minimum data elements for the PUDS inventory could include the date the PUDS was first released, conditions or diseases included in the data set, variables and coding formats contained within the PUDS, and information on how to request the PUDS. If more than one PUDS data set is released by a single surveillance program, the program should clarify how their PUDS data sets are different.

For restricted-access data, the purpose of the log of releases is to be able to track the status and terms of each data sharing agreement (DSA). Thus, the log of releases for restricted-access data should be audited to assess whether the person or persons granted access to restricted-access data are complying with the terms of their DSA. Minimum elements for the restricted-access log may include name and affiliation of the person responsible for compliance with the terms of the DSA and information on how to contact them, names of all collaborators on the project (and information on how to contact them), the list of variables and coding formats re-released, and a checklist of requirements the CDC program needs to verify as per the DSA (for example, if a pre-publication review of the report was required, date the data user sent the report to

CDC for review; or, date the data set was returned to CDC or destroyed, etc).

B. Re-release of State Data as Public-Use Data

Guideline 12: Public-Use Without Restrictions

CDC's re-release of data as a PUDS does not require the use of a DSA. When PUDS are created by CDC programs, they should be made available to all interested users, without restrictions.

CDC programs could make available a PUDS to data requestors who initially request restricted-access data, but who cannot comply with the terms of the DSA.

Refer to the *CDC/ATSDR Policy on Releasing and Sharing Data*⁹ for information about release of data for public use. This Policy indicates "procedures for releasing public-use data should be consistent with the CDC's Public Health Information Network's functions and specifications¹⁷." In addition, the CDC/ATSDR Policy indicates "Each plan [for release of public-use data] should include the following:

- A procedure to ensure that confidential information is not disclosed.
- A procedure to ensure that data is released in a form that does not endanger national security or compromise law enforcement activities.

- Analysis plans and other documentation required by the Office of Management and Budget regulation on data quality¹⁸.
- Instructions for non-CDC users on the appropriate use of the data.
- The date the data will be released, which should be as soon as possible after they are collected.
- The formats in which the data will be released (e.g., ASCII). For each format, give specifications (e.g., variable definitions) and information on standards for transmission.”

The CDC/ATSDR Policy on Releasing and Sharing Data also states: “CIOs may release data without restrictions for public use through the CDC Information Center. Data may also be shared through the CDC/ATSDR Scientific Data Repository, which is managed by CDC’s Epidemiology Program Office.”

Guideline 13: Public Release Disclosure Statement

CDC programs will include written statements about the following responsibilities users of public-use data have, at the time PUDS data are accessed:

- A statement informing PUDS users of their responsibility to maintain confidentiality.
- A statement informing PUDS users of their responsibility not to imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources (for example, the U.S. States) or the CDC public health surveillance program that provided the data, unless the data user and data sources are formally collaborating on the proposed analysis.

- A statement informing users of their responsibility to acknowledge, in all reports based on these data, the original source of the data (for example, the States who collected the data) as well as the name of the CDC public health surveillance program that provided the data.
- The *CDC/ATSDR Policy on Releasing and Sharing Data*⁹ indicates the Public Release Disclosure Statement should include “Information that will preclude misinterpretation of the data.” This should include carefully prepared data documentation (refer to Documentation section of the CDC/ATSDR Policy) to help increase the likelihood that data requestors will interpret the data correctly, as well as information data users would need to know about data limitations. In addition, the CDC/ATSDR Policy indicates that “public-use data sets include a statement notifying the non-CDC user that linking the data to other data for the purpose of identifying individuals is prohibited. In addition, instructions should include a request to report to the CDC ADS any inadvertent discovery of the identity of any person and to make no use of that discovery.”

► **Best Practices for Guideline 13:** CDC NCHS requests that PUDS users agree to:

- “Use the data in this dataset for statistical reporting and analysis only.
- Make no use of the identity of any person discovered inadvertently and advise the Director, NCHS, of any such discovery.

- Not link this dataset with individually identifiable data from other NCHS or non-NCHS datasets.”

The data use agreement for “restricted-access public-use data” from the Agency for Healthcare Research and Quality (AHRQ), Healthcare Cost and Utilization Project (HCUP) and other similar data sets, includes the following statement: “I will make no statement nor permit others to make statements indicating or suggesting that interpretations drawn are those of data sources or AHRQ.”

Guideline 14: Provisional data re-releases, for public use

Provisional (preliminary) data will be re-released for public use only in limited tabular format for the purpose of monitoring trends. No other public uses of provisional data are appropriate, unless the CDC Program specifies that other uses are appropriate, as agreed upon by States. The CDC Program will inform States of their procedure for re-release of provisional data and States, in turn, will indicate their agreement or disagreement with the re-release procedure via their “statement of response” (see [Guideline 3: Requirements imposed by States and Guideline 21: Provisional data re-releases, for restricted-access](#)).

► **Best practices for Guideline 14:** *The Morbidity and Mortality Weekly Report* publishes NNDSS provisional incidence counts

limited to week of report and state of the case-patient's residence at the time of diagnosis; no further demographic or geographic detail is released.

C. Re-release of Data as Restricted-Access Data

Guideline 15: Authentication

When a request for re-release of state-based restricted-access data is received by the CDC program unit, CDC staff will authenticate the identity of the requestor. Authentication methods can be paper-based or electronic. An electronic authentication protocol can use software access control, a physical device, or biometric scan.

► **Best Practices for Guideline 17:** Following are examples.

- Written requests for access to state-based data are required to be on letterhead stationery.
- Oral or email requests from a known individual are considered as needing no further verification.

An electronic authentication protocol can use one or more of the following methods.

- Software access control: Password or challenge phrase; Digital certificate
- Physical device: Hardware “token” (e.g., USB connection); Digital fob (auto-generated passnumber); SmartCard

- Biometric scan

The electronic process for identification-authentication can be linked to authorization "rights" which specify levels of access.

Guideline 16: All requestors wanting to use restricted-access data are required to sign a DSA.

The CDC Program should confirm, via the “statement of response” (see Guideline 3) that the State granted permission for the data to be re-released as a restricted-access data file. In addition, prior to CDC’s re-release of these data, all requestors must sign a DSA which governs the protection and use of these data. The CDC program unit which re-releases state-based data will retain signed copies of the DSA. A DSA may be subsumed in a larger interagency MOU.

► **Best practices for Guideline 16:** The 2002 modification to the HIPAA Privacy Rule permits release of a “limited data set” as long as there is a written data use agreement. This HIPAA standard is consistent with the use of “restricted-access” data and DSAs described within the guidelines section of this report.

Guideline 17: Requirements for a Standard DSA for restricted-access data

Every Standard DSA must include the following elements, which include not only the required criteria listed in the *CDC-ATSDR Policy on Releasing and Sharing Data*⁹ for “special-use agreements,” but also includes additional criteria. Projects with a 308(d) assurance of confidentiality may have additional standards and requirements than described below. If the requestor plans to use the data for research and plan to obtain, or has obtained, approval for the study from an officially sanctioned institutional review board (IRB), the DSA may be abbreviated as follows: the approved protocol or the notice of IRB approval may be substituted for portions of the DSA, as deemed appropriate by the CDC program unit.

- A description of the use to which the data will be put, and limitations on usage of data. The data requestor’s description of their intended use of the data should provide evidence to the CDC program that there is a legitimate public health purpose that justifies the use of the data. The data user should also demonstrate their need for restricted-access data versus other available data, such as a PUDS.
- Information on any laws pertaining to the DSA.
- The names of every person who will have access to the data and specification of procedures for extending the provisions of the DSA to named collaborators (e.g., requiring signed confidentiality pledges, etc).
- The name of a person responsible for care of the data and compliance with the terms of the agreement.

- Mechanisms for preservation of confidentiality. These mechanisms should include both limitations on access (i.e., specified staff only) and technical security practices (such as encryption).
- A list of restrictions on releasing analytic results.
- No attempt to link dataset with any other dataset without prior CDC permission (see [Guideline 18: Required Addendum to the Standard DSA when a Data Requestor Plans to Link Restricted-Access Data to Other Data](#)).
- No further release of data to other parties without prior CDC permission (see [Guideline 19: Required Addendum to the Standard DSA when a Data Requestor Plans Further Releases of Data to Other Parties, from Restricted-Access Data](#)).
Requests from legal authorities (such as under conditions of a declared public health emergency) or FOIA requests must be referred to the CDC data steward.
- Notification of CDC data steward if any individual person represented in the dataset is inadvertently identified during approved usage.
- Limitation of right of access to data based on the role of an individual, with return or destruction of dataset when the requestor changes positions in the agency or leaves the agency.
- Return or destruction of dataset and all derived files when use is completed (the term "use" in this sense includes a specified plan for re-analyzing the data after the initial analysis is completed).
- A written statement informing users of their responsibility not to imply or state, either in written or oral form, that interpretations based on the data are those of the original data sources (for example, the U.S. States) or the CDC public health surveillance

program that provided the data, unless the data user and data sources are formally collaborating on the proposed analysis.

- A written statement informing users of their responsibility to acknowledge, in all reports based on these data, the original source of the data (for example, the States who collected the data) as well as the name of the CDC public health surveillance program that provided the data.
- A description of the penalty that may be imposed on the data user for breaching the terms of the DSA.
- Provisions that govern emergency requests for identifiable or otherwise confidential data (See also Guideline 22: Emergency requests for data).
- For DSAs with CDC staff acting as a data user, include the following elements on the DSA:
 - A statement indicating that if the CDC data user plans to publish a report that singles out a specific State or City in the discussion section of the report, the CDC Program should send a courtesy message and copy of the report to the State, before the expected publication date. This requirement does not apply in situations where a table in the report includes all 50 States. It is understood that the CDC programs will use their judgment in determining when to contact the State. The intent of this requirement is to help ensure the State has time to prepare a response or reaction to news media or to other inquiries when the CDC report is published.
 - A statement describing how the CDC program intends to monitor compliance with the terms of the DSA, such as pre-publication review of reports,

presentations, maps, graphs, etc (see Guideline 20: DSA compliance monitoring).

► **Best practices for Guideline 17:** The *CDC/ATSDR Policy on Releasing and Sharing Data* indicates that data that cannot be publicly shared may be shared with restrictions with public health partners. The CDC/ATSDR Policy indicates “Restrictions can be imposed because of legal constraints or because releasing the data would risk (1) disclosing proprietary or confidential information or (2) compromising national security or law enforcement efforts...For restricted data, special data sharing agreements must be developed.” The CDC/ATSDR Policy also indicates, data shared with restrictions can be shared: (1) using CDC-controlled data centers (such as NCHS has developed), (2) by licensing non-CDC researchers to use certain data, if CDC chooses to consider this licensing option in the future, or (3) through a special-use agreement. This guideline, and the Standard DSA, applies to “restricted-access data” shared outside of CDC-controlled data centers.

The South Carolina Office of Research and Statistics application for release of data includes the following statement to data requestors: “All releases of data must contain the following

statement: NOTICE: THIS INFORMATION IS FROM THE RECORDS OF THE OFFICE OF RESEARCH AND STATISTICS, BUDGET AND CONTROL BOARD, SOUTH CAROLINA. OUR AUTHORIZATION TO RELEASE THIS INFORMATION DOES NOT IMPLY ENDORSEMENT OF THE STUDY OR ITS FINDINGS.”

CDC/EPO provides the following information regarding acknowledgement to users of data from the National Notifiable Diseases Surveillance System:

“We request that any published material derived from NNDSS data acknowledge 1) the U.S. State and Territorial Health Departments that collect the data from a range of case ascertainment sources (e.g., health-care providers, hospitals, laboratories) and report these data to CDC; 2) CDC’s National Notifiable Diseases Surveillance System; and 3) the Surveillance Systems Branch, Division of Public Health Surveillance and Informatics, Epidemiology Program Office (responsible for preparing and aggregating state-based NNDSS data for dissemination.

Guideline 18: Required Addendum to the Standard DSA when a Data Requestor Plans to Link Restricted-Access Data to Other Data

Restricted-access data include identifiable or potentially identifiable data. The data set derived from linking a restricted-access data set to another data file may be even more individually identifiable than the original data. Thus, there is a need to ensure disclosure review takes into account the variables included after the linkage.

The CDC Program interested in re-releasing restricted-access data for a linked data analysis should obtain, or require the data requestor to obtain, written permission from the data providers (the States contributing the data) for the proposed linked analysis. Prior to seeking permission from the data providers, the data requestor should complete and sign the standard DSA (see Guidelines 16-17) and, in addition, attach an addendum to the DSA which includes the following information, so the CDC program and data providers can determine whether to approve the data request: 1) source and description of the data file the restricted-access data will be linked to, 2) written description of the variables and coding formats to be included in the final linked file, and 3) description of the data requestor's plan for conducting additional disclosure review to ensure that variables contributed in the linking process do not lead to re-identification of the individual described in the original data file.

► **Best practices for Guideline 18:** Examples of special procedures for linked analyses are:

- "separation of duties", where no single individual is enabled to conduct all of the steps in the linkage process

- post-linkage de-identification. Standard de-identification methods should be used, such as numerator and denominator cell aggregation or suppression rules.

GAO Report #GAO-01126SP titled “RECORD LINKAGE AND PRIVACY: Issues in Creating New Federal Research and Statistical Information²³” may serve as a useful reference of techniques which can be employed to ensure privacy protection for data linkages.

Linkage can be conducted inside a CDC-controlled data center. This guideline applies to “modified” data shared outside of such centers. Data shared outside CDC-controlled data centers are partially or substantially modified, as needed, in order to minimize the likelihood of breaches of confidentiality.

Guideline 19: Required Addendum to the Standard DSA when a Data Requestor Plans Further Releases of Data to Other Parties, from Restricted-Access Data

Restricted-access data can be released further to other parties as de-identified data, in one of two ways: 1) by creating a de-identified data set (i.e., a PUDS) from the restricted-access data set, then disseminating data from the PUDS, or 2) by generating de-identified

data directly from the restricted-access data set (where the restricted-access data file, by definition, includes identifiable or potentially identifiable data).

If the requestor plans to release de-identified data generated directly from a restricted-access data file (situation #2 described above), a procedure must be implemented to ensure the generated data have been de-identified appropriately. In this situation, the data requestor is required to submit an addendum to the standard DSA (See Guidelines 16-17) describing the procedures that will be implemented to audit the results of the data generated for further release to other parties.

If the requestor plans to release de-identified data that are generated from a de-identified data set created from the restricted-access data set, an addendum to the standard DSA is not required (situation #1 described above).

► **Best practices for Guideline 19:** If the requestor plans release via an on-line interactive query system which generates tables from restricted data, an automated algorithm for de-identification must act prior to release, and its results must be checked by an automated audit protocol. *An automated audit protocol assesses disclosure risk against pre-determined thresholds.*

Guideline 20: DSA compliance monitoring

The CDC program unit which re-releases state-based data will monitor compliance with the terms of the DSA.

► **Best practices for Guideline 20:** A passive approach to compliance monitoring is acceptable, as long as the following criteria are met:

- The data user is informed of the penalty for not complying with the terms of the DSA. The intent of the penalty is to deter breaches in compliance.
- The data user is fully educated about their responsibilities in using the data.
- The data steward institutes a process for logging compliance problems they become aware of.
- The CDC program takes appropriate actions to resolve the identified problem and identifies (if possible) ways similar types of problems may be avoided in the future.

Examples of active compliance monitoring methods include:

- pre-publication review of reports, articles, graphs, maps, or tables
- prior review of presentations based on the dataset

- annual letters sent by data stewards to confirm whether the data requestor's use of the dataset has been completed and whether the data requestor has taken steps to either destroy or return the dataset.

Pre-publication or pre-presentation review can include both privacy protection as well as accuracy of scientific inferences.

Guideline 21: Provisional data re-releases, for restricted-access

Access to provisional microdata in the format sent by States, which are not reviewed and are not modified, if necessary to prevent breaches in confidentiality, should be granted only to the State providing the data, and to the CDC program unit. The purposes of such access to provisional microdata should only be for data quality review and for limited surveillance/assessment purposes, (e.g., for confirming surveillance findings, monitoring trends, detecting aberrations, and identifying the need for immediate interventions). No other uses of provisional unreviewed or unmodified microdata are appropriate, unless the CDC Program specifies that other uses are appropriate, as agreed upon by States.

Provisional restricted-access modified microdata (microdata that are partially or substantially modified, as needed, in order to minimize the likelihood of breaches of confidentiality), can be provided to other States, under the standard DSA.

The CDC Program will inform States of their procedure for re-release of provisional data and States, in turn, will indicate their agreement or disagreement with the re-release procedure via their “statement of response” (see [Guideline 3: Requirements imposed by States](#) and [Guideline 14: Provisional data re-releases, for public use](#)).

Best practices for Guideline 21: Data quality review is considered complete upon mutual agreement by the state and CDC, once the maximum achievable quality has been attained. Explicit criteria for data finalization should be documented and include adequate time for corrections from data providers and for case investigation to establish final case classification.

Guideline 22: Emergency requests for data

Requests for restricted-access data in a public health emergency that pose an important public health question, have a high likelihood of yielding results important for understanding, controlling, or responding to a public health emergency, and are consistent with CDC program data re-release procedures should undergo expedited review and be fast-tracked for processing. As with all data re-releases, the *CDC/ATSDR Policy for Releasing and Sharing Data* indicates released data should not compromise privacy concerns, federal and state confidentiality concerns, proprietary interests, national security interests, or law enforcement activities.

Health conditions related to terrorism events may be very rare events (have low incidence in the population), and may be highly publicized in the media (as evidenced by the anthrax contamination of the U.S. mail in 2001), thus numerator and denominator cell size aggregation and suppression rules may not be appropriate for these types of events. Data re-release for these events may require the development of special data sharing agreements. Emergency requests for restricted-access data that violate existing CDC program data release procedures should undergo expedited review by the CIO data-release review board in order to assess whether the request should be denied on the basis that it violates the CDC program data release procedures or should be approved with special restrictions and constraints outlined in a special data sharing agreement. Referral to the CIO data-release review board may help the board prospectively develop criteria for how to address similar data requests in the future. The CIO data-release review board has the authority to approve requests for data release that violate program-specific data release procedures, as long as there is sufficient justification for such approval and the release is consistent with the *CDC/ATSDR Policy on Releasing and Sharing Data*⁹. A special data sharing agreement will need to be developed and tailored to meet the needs of the particular emergency situation.

Cross-reference table

Microdata	Tabular data
Guidelines 1-22	Guidelines 1-5, 7-9, 14, 19

5. Comments Regarding Adoption of the CDC-ATSDR-CSTE Data Release Guidelines for Re-release of State Data

5.1 Proposed deadline for CDC’s implementation of the Guidelines

CDC and ASTDR programs having surveillance systems that fall within the scope of the CDC-ATSDR-CSTE data release guidelines should have one year following the publication of the data release guidelines to establish program-specific procedures for re-release of State data based on these Guidelines, unless an appeal for an extension is requested from and granted by the CDC Associate Director for Science (ADS). CDC CIOs should be responsible for ensuring that the guidelines are implemented either through the establishment of a CIO data-release review board (see the *CDC/ATSDR Policy on Releasing and Sharing Data*⁹), which might report to the CIO Associate Director for Science and might include the CIO Information Resources Manager and relevant data stewards, or CIOs might wish to implement the policy using an alternative oversight mechanism. Since CDC program data stewards will most likely be the primary staff responsible for writing program-specific procedures, under the direction of the CIO data-release review board or another oversight mechanism, CDC may wish to consider establishing an across-CIO forum for data stewards to use in order to brainstorm and share suggestions for implementing the CDC-ATSDR-CSTE data release guidelines.

5.2 Development of curricula for “special training”

CDC and ATSDR should determine the specific content of the curricula for “special training” that data stewards and other members of the CIO data-release review board (or other group having oversight responsibility for data re-releases) should have (as per Guideline 2: Training). This should include training in confidentiality protection and disclosure risk assessment and control (as per Guideline 2: Training) at a minimum, but it

may also be beneficial to consider including training in other issues, such as enterprise-wide security standards for public health surveillance, or any other subjects CDC identifies if it conducts a staff training needs assessment. The specific issues to cover within the above subjects and the frequency of staff training are left to the discretion of CDC. However, CDC should provide a mechanism for testing the staff who received training and the staff receiving training should be required to pass a post-training test with a grade that demonstrates comprehension of the training material. CDC may wish to develop training modules on the above subjects itself or contract with experts in the above subjects to develop training materials and resources.

5.3 Development of a data set inventory to facilitate disclosure risk assessment

Disclosure risk assessment is performed to estimate, either qualitatively or quantitatively, the probability that a data set poses a high or low risk of re-identification in terms of the information it contains about individuals and the status of their health. Since the risk of re-identification may be increased if a one data set can be linked to another data set, CDC and ATSDR data stewards should be aware of the data sets other CDC components release that could have the potential for linkage with data sets their own programs release. To help facilitate this aspect of disclosure risk assessment, we recommend that CDC and ATSDR compile an inventory of data sets that have already been released and that are eligible for release soon, that will be updated regularly. The inventory should be posted on the CDC Intranet in a queriable format and should include the name of the CDC program releasing the data set, information about how to contact

the data steward for that data set, and data set documentation (see the “Documentation” section of the *CDC/ATSDR Policy on Releasing and Sharing Data*⁹ for recommended categories of information data set documentation should include), including the names of diseases or conditions the data are tabulated about, and the variables and coding formats used.

5.4 Current standards for de-identifying data sets and performing disclosure review assessment

It is the intention of this report to encourage CDC-ATSDR Programs to re-release data as much as possible through the use of PUDS. The creation of a PUDS will require CDC-ATSDR programs to go through a data de-identification process since PUDS data do not contain individually identifiable information. The current standards used to help de-identify data sets are as follows: 1) the FCSM’s Statistical Working Paper 22 on statistical disclosure methodology,¹⁹ which includes an educational primer on statistical disclosure limitation, 2) the *Checklist on Disclosure Potential of Proposed Data Releases*, developed by the Interagency Confidentiality and Data Access Committee, FCSM²⁰, and 3) The Health Insurance Portability and Accountability Act (HIPAA) Privacy Rule²¹. However, the HIPAA Privacy Rule’s Safe Harbor method of de-identification is deemed inadequate protection for public health agencies to use for de-identifying data sets because public health agencies collect many more demographic variables than do covered health entities. In addition, public health agencies are expected to have a much higher level of sophistication with regard to disclosure review than covered entities.

Other useful materials on confidentiality protection have been developed and will be useful to those involved in data protection and re-release, such as a book published in 2001 titled *Confidentiality, Disclosure, and Data Access: Theory and Practical Applications for Statistical Agencies*³; a 1993 book titled *Private Lives and Public Policies, Confidentiality and Accessibility of Government Statistics*⁴; the Institute of Medicine's report *Protecting Data Privacy in Health Services Research*²²; and the Government Accounting Office report on record linkage and privacy²³. In addition, the FCSM's Confidentiality and Data Access Committee has prepared a document titled "Identifiability in Microdata Files²⁴" that is instructive in terms of helping one think through the factors which could increase the re-identification potential of a data set.

5.5 Development of instructions data stewards can use to create PUDS for data re-releases, including FOIA requests.

CDC should consider the feasibility of developing specific instructions for creating PUDS that CDC program data stewards could use. If feasible, CDC should itself develop or contract with others to create PUDS development instructions. Having PUDS development instructions would also help data stewards to create de-identified data sets for Freedom of Information (FOIA) data requests, since the CDC FOIA office does not currently provide any standardized criteria to CDC data stewards to help assist them in creating de-identified data sets released in response to FOIA requests.

5.6 Evaluations to assess whether a breach of confidentiality has occurred

Guideline 1 states that potential confidentiality breaches should be reported to the CDC program unit Privacy Officer and that the Privacy Officer should report this information to the CIO data-release review board. This passive approach to ascertaining potential confidentiality breaches assumes that CDC programs will receive such reports. CDC should consider the feasibility of taking a more active approach to identifying confidentiality breaches. If feasible to do so, CDC may wish to itself develop or contract with others to develop standard criteria for CDC programs to use in conducting these evaluations.

5.7 Establish a CDC Intranet site where materials referenced in this report, from various web sites, are archived.

This report cites various materials that are currently posted on the Internet pertaining to “training” issues, such as data release policies, confidentiality protection, or disclosure review assessment that would be useful to preserve for use with this report. In order to preserve the future availability of these materials, CDC should consider creating an Intranet site where these materials are archived.

5.8 Feedback to CSTE regarding CDC's implementation of the Guidelines

CDC should advise CSTE on at least an annual basis during the implementation phase of these guidelines, on the status of completion of implementation. In addition, CDC should communicate with CSTE regarding the results of evaluations conducted after the guidelines have been implemented by CDC programs, particularly if the results of the evaluations indicate that a revision of the guidelines is warranted.

6. DRGWG Members

CDC Members

CIO	Primary Representative	Alternate Representative
ATSDR	Maureen Orr	Shannon Rossiter
EPO	Ruth Ann Jajosky (DRGWG co-chair)	
NCBDDD	Leslie O'Leary	
NCCDPHP	Mary Hutton	Nedra Whitehead
NCEH	Sharunda Buchanan	
NCHS	Julie Kowaleski	Alvan Zarate
NCHSTP	Pat Sweeney	Sam Costa
NCID	Katherine Robinson	
NCIPC	vacant as of March 2002	
NIOSH	William Eschenbacher	Robert Castellan
NIP	Gail Horlick	

OD	Kenya Ford
PHPPO	vacant as of April 22, 2002

Former CDC DRGWG Members

ATSDR	Wendy Kaye
NCID	Bob Pinner
NCIPC	John Horan
NCCDPHP	Luann Rhodes
PHPPO	William Yasnoff

CSTE Members

Affiliation	Representative
Washington State Department of Health	Steven C. Macdonald (DRGWG co-chair)
Iowa Department of Health	Patricia Quinlisk
Washington State Department of Health	Jac Davies
Kansas Department of Health and Environment	Gianfranco Pezzino
Virginia Department of Health	Jennifer Haussler

7. Acknowledgements:

The DRGWG members wish to thank Aun Lor in CDC/EPO who worked with Betsey Dunaway, CDC Confidentiality and Privacy Officer in the Management Analysis and Services Office (MASO), to develop the document included in Appendix A of this

report, which summarizes the Freedom of Information Act, The Privacy Act, and Confidentiality Assurances (308(d)) and Certificates of Confidentiality (301(d)); Betsey Dunaway for the information and insights she shared with the DRGWG; Donna Stroup, chair of the Excellence in Science sub-committee on data release and sharing, and the members of her sub-committee who drafted the *CDC/ATSDR Policy on Releasing and Sharing Data*⁹; Paula Kocher, CDC Office of General Counsel; and lastly, a special thanks is due to the CDC, CSTE, and State Health Department leadership and supervisory staff for recognizing the importance of the work undertaken by the DRGWG and for allowing their staff to dedicate time and resources to this effort.

8. Glossary

Audit trail: This term refers to the maintenance of information, in a logbook or database, pertaining the request for and release and use of individually identifiable data.

Authentication: This term refers to the process by which the identity of a person requesting access to individually identifiable data (restricted-access data) is verified.

Automated audit protocol: In terms of disclosure risk control, this term refers to the use of linear programming to identify complementary cell suppressions for a primary cell suppression and to audit the proposed cell suppression pattern to see if it provides the required level of protection. Research seems to indicate that linear programming methodologies provide good but not optimal results. For this reason, it is not enough to just perform an automated audit for secondary cell suppression. The result of the algorithm needs to be checked to see if it is successful.

Bottom-coding: Bottom-coding is a technique used to mask microdata that involves creating categories for data values that are below a certain level. This method differs from aggregation, in that only data values below a certain threshold are grouped, rather than all values in a field. *See top-coding also.*

Cell suppression: One of the most commonly used ways of protecting sensitive cells is through cell suppression. It is obvious that in a row or column with a suppressed sensitive cell, at least one additional cell must be suppressed, or the value in the sensitive cell could be calculated exactly by subtraction from the marginal total. For this reason, certain other cells must also be suppressed. The suppression of a sensitive cell is termed a primary cell suppression. Suppression of other cells to prevent one from calculating the value in the sensitive cell is termed complementary (or secondary) cell suppression.

Computational disclosure control: This term refers to the process by which data values are aggregated to increase the granularity of specific variables, such as grouping age into age groups prior to data release.

Confidentiality: This term refers to the treatment of information that an individual or institution has disclosed in a relationship of trust, with the expectation that it will not be divulged to others in ways that are inconsistent with the understanding of the original disclosure. It encompasses access to and disclosure of information in accordance with requirements of law and/or official policy²⁵.

Confidentiality breach: “An unauthorized release of identifiable or confidential data or information, which may result from a security failure, intentional inappropriate behavior, human error, or natural disaster. A breach of confidentiality may or may not result in harm to one or more individuals.” (Source: Washington State Department of Health “Guidelines for Working With Small Numbers, Glossary” accessible at URL: <<http://www.doh.wa.gov/Data/Guidelines/SmallNumbers.htm>>, accessed on April 11, 2002.)

Confidentiality Officer: See the definition of ‘Privacy Officer’ in the glossary. In this report, the Privacy Officer and Confidentiality Officer are synonymous terms.

Data access: Data access is a general term referring to situations involving either data release or data sharing.

Data dissemination: Dissemination refers to any mechanism by which data are made available to users. It includes mechanism whereby data are released to users as well as where data are made available without being released.

Data release: Dissemination of data either in a public use file or as a result of an ad hoc request which results in the data steward no longer controlling the use of the data. Data may be released in a variety of formats including, but not limited to, tables, microdata (person records), or on-line query systems.

Data sharing: Granting certain individuals or organizations access to data that contain individually identifiable information with the understanding that individually identifiable or potentially identifiable data cannot be re-released further unless a special data sharing agreement governs the use and re-release of the data and is agreed upon by CDC and the data providers.

Data sharing agreement: A data sharing agreement is a mechanism by which a data requestor and CDC Program can define the terms of data access that can be granted to requestors.

Data steward: A person responsible for the management, processing, documentation, integrity, and security of information in a data system. Data stewards can assume the responsibilities that privacy officers may have, such as the developing and implementing data confidentiality procedures, and being responsible for clearing responses to data requests for a surveillance system. (See the definition of privacy officer in the glossary.)

Disclosure: In this report, ‘disclosure’ refers to the public disclosure of information about a person, which data have been collected about. A disclosure may occur as a result of a confidentiality breach. The definition of disclosure used in the HIPAA Privacy Rule is different than the definition in this report. For purposes of HIPAA, ‘disclosure means the release, transfer, provision of access to, or divulging in any other manner of information outside the entity holding the information.’

Disclosure (risk) assessment: A systematic review of a data file conducted to determine if any of the proposed contents present an unacceptable risk of individual disclosure. Disclosure risk assessment and control are usually conducted in order to prepare a public-use data set and they can also be conducted when preparing a data set that is potentially linkable to another released data set.

Disclosure (risk) control (also referred to as disclosure limitation or disclosure protection): The application of measures to reduce the possibility of identifying an individual through the characteristics available in a data file. Disclosure risk assessment and control are usually conducted in order to prepare a public-use data set and they can also be conducted when preparing a data set that is potentially linkable to another released data set. Disclosure control includes steps taken to modify or suppress information that might identify an individual directly or indirectly before the data are made available to others for analysis (see page 3 of the Doyle book³). Perturbative disclosure control methods distort (alter) the data before it is released while nonperturbative methods do not alter the data, but instead partially suppress or reduce the detail of the original data set (see page 112 of the Doyle book³). Examples of disclosure control include cell suppression, adding statistical noise, data swapping, top- and bottom-coding, blanking and imputing for randomly selected records, and blurring data (replacing a reported value by an average value).

Individually identifiable data: This term refers to data or information which can be used to establish individual identity, either “directly,” using items such as name, address, or unique identifying number, or “indirectly” by linking data about a case-individual with other information that uniquely identifies them.

Microdata: A data file containing information in which each record provides information at the unit of data collection, e.g., individual persons, events, households, or establishments.

Penalties: Penalties for a breach of confidentiality can range from imposing fines or a prison sentence to disciplinary action, barring an individual from receiving data in the future, or termination of employment or contract. Penalties can be established to differentiate willful from inadvertent disclosure and they can be tailored to the type of party responsible for the breach of confidentiality--an employee, contractor, or external data requestor.

Population-based data: Population-based data represent either a complete count of cases occurring within a given population or a statistical sample of all cases occurring within a given population.

Predecisional exemption: The Freedom of Information Act’s “Predecisional” exception is explained in 5 U.S.C. § 552(b)(5) as “inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than an agency in litigation with the agency.” The term “predecisional” has been traditionally defined by the courts as meaning “antecedent to the adoption of an agency policy.”²⁶

Privacy: Privacy refers to the right of individuals to hold information about themselves in secret, free from the knowledge of others²⁷.

Privacy Officer: A person who develops and implements a data system's confidentiality policy and is responsible for clearing responses to data requests for a surveillance system. Data stewards may act as privacy officers. (See definition of data steward in the glossary). In this report, the terms Privacy Officer and Confidentiality Officer are being used synonymously.

Proprietary: Produced or collected in such a way that exclusive rights may apply.

Provisional or preliminary data: These terms refer to data that are subject to change based upon further case investigation and evaluation.

Public health emergency: An occurrence or imminent threat of an adverse health event caused by epidemic of pandemic disease, infectious agent, biologic or chemical toxin, environmental disaster, or any agent that poses a real and substantial risk for a significant number of human fatalities or case of permanent or long-term disability.

Public-Use Data: Data available to any requestor. Public-use data are sometimes referred to as "de-identified data" and include public-use data sets (PUDS), tables, or other data formats, with all individually identifiable data or information removed, and with the remaining fields modified or suppressed so as to reduce disclosure risk as much as reasonably possible and such that it is not possible to create any tables that violate the numerator or denominator cell size rules for a given surveillance system.

Public-Use Data Set (PUDS): See Public-Use Data.

Re-release: States release their data to CDC. Then, CDC uses and re-releases these data in various formats, including CDC reports, publications, graphs, maps, and presentations. In addition, CDC may re-release data files to data users that are either internal or external to CDC. The term re-release applies to CDC's re-release of data that the States initially provided to CDC through their release procedures.

Restricted-access: This term refers to allowing the use of an Agency's microdata under controlled conditions. Restricted-access may mean allowing the use of an agency's data only to those who sign a formal data sharing agreement or permitting access to the data only at CDC-controlled research data centers, where CDC exercises direct supervision of the data use in order to protect confidentiality.

Security: Security refers to the mechanisms (administrative, technical, physical) by which privacy and confidentiality policies are implemented in computer and telecommunication systems.

Top-coding: Top-coding is a technique used to mask microdata that involves creating categories for data values that exceed a certain level. This method differs from aggregation, in that only data values above a certain threshold are grouped, rather than all values in a field. *See bottom-coding also.*

9. Appendices

Appendix A: History leading up to the establishment of the CDC-CSTE Intergovernmental Data Release Guidelines Working Group

CDC and CSTE have been engaged in extensive discussions over issues related to CDC's re-release of state-based data. A June 1996 CSTE document, entitled *Data Release Guidelines of the Council of State & Territorial Epidemiologists for the National Public Health Surveillance System*, refers to these earlier discussions: "In 1985, CDC and CSTE jointly negotiated a policy for the release of data from CDC's notifiable disease surveillance system to facilitate its use for public health, while preserving the confidentiality of the data." Similarly, the 1996 agreement cites "A revised data release policy exclusively for AIDS was approved by the CSTE Executive Committee in 1995." The 1996 agreement was intended to update and broaden the 1985 policy, and it was anticipated by CSTE that it would subsequently be implemented by CDC in all of its separate CIOs. Although implementation was successful in a few program units (most notably the National Notifiable Diseases Surveillance System in the Epidemiology Program Office), CDC failed to implement the agreement in most other CIOs.

In 1999, the Surveillance Systems Branch in the Epidemiology Program Office (EPO), CDC prepared draft data release procedures for the National Notifiable Diseases Surveillance System (NNDSS), which were based on the June 1996 *Data Release Guidelines of the Council of State and Territorial Epidemiologists for the National Public Health Surveillance System*. The draft 1999 NNDSS procedures were not intended to conflict with or revise CSTE's June 1996 guidelines. Instead, the draft 1999 NNDSS procedures were intended to clarify specific issues related to the release of NNDSS data and to formalize the 1996 CSTE guidelines. Surveillance Systems Branch staff sought consultation from CSTE's Surveillance Committee regarding implementation issues and problems they had experienced since 1996 related to ambiguities in CSTE's June 1996 data release guidelines. During this consultation, the Surveillance Systems Branch staff also asked CSTE of their interest in expanding the cell size suppression rules described in the June 1996 data release guidelines, from a consideration of not only the number of persons in the numerator of a table cell but to also to include a consideration of the number of persons in the denominator of a table cell. The CSTE Surveillance Committee expressed interest in working with the Surveillance Systems Branch to finalize the draft 1999 NNDSS procedures, including preparing an expansion of the cell size suppression rules, and they also expressed interest in learning about other CDC program practices related to re-release of state-based data, including data CDC obtains through cooperative agreements. During the consultation, several CSTE members recollected that their expectation back in 1996 was that CSTE's June 1996 data release guidelines would be implemented CDC-wide; however, subsequent inquiry in year 2000 into this issue by the

now defunct CDC Surveillance Coordination Group indicated that other CDC CIOs were unaware of the CSTE's June 1996 data release guidelines. Shortly after the initial Surveillance Coordination Group inquiry, CSTE informally informed the Surveillance Systems Branch of their intent to send a letter to the CDC Director about the need to implement uniform data release practice at CDC for the re-release of state-based data held at CDC. In addition, CSTE indicated their desire to address the uniformity of data release issue within CDC would temporarily delay the finalization of the 1999 NNDSS data release procedures.

In a letter mailed in May, 2000 to the CDC Director, the CSTE President expressed interest in establishing a joint CDC-CSTE working group to review CDC program-level data re-release practices pertaining to state-based data and to develop and implement uniform CDC-wide data re-release guidelines for state-based data. In response, Barbara Holloway, Acting Director of EPO, sent a letter in June, 2000 to the CSTE President indicating support for such a collaboration and stating the CDC Health Information and Surveillance Systems Board (HISSB) Surveillance Coordination Group would play a critical role in addressing these issues. The CDC Surveillance Coordination Group chairman established the CDC-CSTE Intergovernmental Data Release Guidelines Working Group in February 2001. Then, in the Fall of 2001, the CDC Excellence in Science Committee's data release and data sharing sub-committee assumed administrative oversight of the DRGWG, following the CDC administration dissolving the HISSB and its working groups, including the Surveillance Coordination Group.

Appendix B: Overview of the Freedom of Information Act, the Privacy Act, Confidentiality Assurances (308(d)), and Certificates of Confidentiality (301(d))

Introduction

Under the **Freedom of Information Act** (FOIA) (Title 5 United States Code §552 or 5 USC 552), **all** Federal agency records are subject to disclosure unless covered (in whole or part) by one (or more) of nine exemptions. The **Privacy Act** applies only to records in "systems of records*" [defined in 5 USC §552a(a)(5)], from which information is retrieved by an individual's name or other identifier. Such records are subject to release to individuals asking for their own records, to other requesters with the signed consent of the named individual, or to other requesters without a subject's consent under limited conditions specified in the Privacy Act. Also, Sections 301(d) (42 USC 241(d)-**Certificates of Confidentiality**) or 308(d) (42 USC 242m(d)-**Confidentiality Assurances**) of the Public Health Service Act, provide additional protection for the identities of individuals or institutions within records.

***Definition** - The term "system of records" means a group of any records under the control of any federal agency from which information is retrieved by the name of the individual or by some identifying number, symbol, or other identifying particular assigned to the individual.

Freedom of Information Act (Title 5 USC 552)

The Freedom of Information Act (FOIA) provides that, upon receiving a written request from any person, a federal agency must release any requested agency record unless that record falls within one of the nine FOIA exemptions. FOIA applies to only federal agencies, and covers only records in the possession and control of those agencies except in certain narrow instances involving grantee-held data.

- Exemptions from FOIA (Title 5 USC 552b)
 1. Protects from disclosure national security information concerning national defense or foreign policy provided that it has been properly classified pursuant to executive Order 12,958.
 2. related solely to the internal personnel rules and practices of an agency;
 - (a) Internal matters of a relatively trivial nature;
 - (b) More substantial internal matters, the disclosure of which would risk circumvention of a legal requirement.
 3. specifically exempted from disclosure by statute (other than section 552b of this title), provided that such statute:
 - (a) requires that the matter be withheld from the public in such a manner as to leave no discretion on the issue; or

- (b) establishes particular criteria for withholding or refers to particular types of matters to be withheld
 - 4. trade secrets and commercial or financial information obtained from a person that is privileged or confidential;
 - 5. inter-agency or intra-agency memorandums or letters which would not be available by law to a party other than agency in litigation with the agency;
 - 6. personnel and medical files and similar files the disclosure of which would constitute a clearly unwarranted invasion of personal privacy;
 - 7. records or information compiled for law enforcement purposes, but only to the extent that the production of such law enforcement records or information:
 - (a) could reasonably be expected to interfere with enforcement proceedings;
 - (b) would deprive a person of a right to a fair trial or an impartial adjudication;
 - (c) could reasonably be expected to constitute an unwarranted invasion of person privacy;
 - (d) could reasonably be expected to disclose the identity of a confidential source, including a State, local or foreign agency or authority or any private institution which furnished information on a confidential basis, and, in the case of a record or information compiled by a criminal law enforcement authority in the course of a criminal investigation or by an agency conducting a lawful national security intelligence investigation, information furnished by a confidential source;
 - (e) would disclose techniques and procedures for law enforcement investigations or prosecutions, or would disclose guidelines for law enforcement investigations or prosecutions if such disclosure could reasonably be expected to risk circumvention of the law; or
 - (f) could reasonably be expected to endanger the life or physical safety of any individual.
 - 8. contained in or related to examination, operating, or condition reports prepared by, on behalf of, or for the use of an agency responsible for the regulation or supervision of financial institutions; or
 - 9. geological and geophysical information and data, including maps, concerning wells.
- Any reasonably segregable portion of a record shall be provided to any person requesting such record after deletion of the portions which are exempt under this subsection. The amount of information deleted shall be indicated on the released portion of the record, unless including that indication would harm an interest protected by the exemption in this subsection under which the deletion is made. If technically feasible, the amount of information deleted shall be indicated at the place in the record where such deletion is made.

Privacy Act (5 USC 552a)

The Privacy Act applies to records maintained by a federal agency in a system of records in which the primary method for data to be retrieved is by full names, social security numbers, or other identifying particulars.

The Privacy Act states “No agency shall disclose any record which is contained in a system of records by any means of communication to any person, or to another agency, except pursuant to a written request by, or with the prior written consent of, the

individual to whom the record pertains.” The Act goes on to state the following exceptions, which are discretionary:

Disclosures Permitted by the Privacy Act

The Privacy Act permits disclosure without a subject’s consent in certain circumstances:

1. to those officers and employees of the agency which maintains the record who have a need for the record in the performance of their duties;
2. required under section 552 (FOIA) of this title;
3. for a routine use (disclosure of identifiable data outside the Department for a purpose compatible with the purpose for which the data were collected);
4. to the Bureau of the Census for purposes of planning or carrying out a census or survey or related activity;
5. to a recipient who has provided the agency with advance adequate written assurance that the record will be used solely as a statistical research or reporting record, and the record is to be transferred in a form that is not individually identifiable;
6. to the National Archives and Records Administration as a record which has sufficient historical or other value to warrant its continued preservation by the United States Government;
7. to another agency or to an instrumentality of any jurisdiction within or under the control of the United States for a civil or criminal law enforcement activity if the activity is authorized by law, and if the head of the agency or instrumentality has made a written request to the agency which maintains the record specifying the particular portion desired and the law enforcement activity for which the record is sought;
8. to a person pursuant to a showing of compelling circumstances affecting the health or safety of an individual if upon such disclosure notification is transmitted to the last known address of such individual;
9. to either House of Congress, or, to the extent of matter within its jurisdiction, any committee or subcommittee thereof, any joint committee of Congress or subcommittee of any such joint committee;
10. to the Comptroller General, or any of his authorized representatives, in the course of the performance of the duties of the General Accounting Office;
11. pursuant to the order of a court of competent jurisdiction;
12. to a consumer reporting agency in accordance with section 3711 f (Title 31 USC 3711f – Money and Finance: Collection and Compromise).

- The Privacy Act does not protect some records with identifiers:

1. Records of dead persons;
2. Records of individuals who are not U.S. citizens or lawfully admitted aliens;
3. Records not the property of a federal government agency (Executive Branch);
4. Records not containing full names, social security numbers, or other unique identifiers;

5. Records containing names but not primarily filed and retrieved by name or social security number (e.g., job announcements).

Confidentiality Assurance (Public Health Service Act §308(d), 42 USC §242m(d))

Under the authority in Section 308(d) of the Public Health Service Act, CDC can provide confidentiality protection to a project when necessary to achieve the project's objectives, and when the respondents would not otherwise furnish valid sensitive information without that assurance. 308(d) protects information collected for a project from being used for any purpose other than the purpose for which it was collected unless the person or establishment from which the data were obtained has consented to such use.

Confidentiality assurances protect against disclosures under a court order and provide protections that the Privacy Act does not. For example, the Privacy Act only protects individual participants, but confidentiality assurances can also protect institutions.

Confidentiality protection granted by the CDC promises participants and institutions that their data will be shared only with those individuals and organizations listed in the consent form and/or the Assurance of Confidentiality Statement for the project.

Projects that involve the collection of sensitive information frequently need confidentiality protection. Sensitive information includes (but is not limited to) data collection on sexual behaviors, drug uses, mental health status, or other information that if released could reasonably be damaging to an individual's financial standing, employability, or reputation.

The full text of Section 308(d) of the Public Health Service Act follows:

“No information, if an establishment or person supplying the information or described in it is identifiable, obtained in the course of activities undertaken or supported under section [304](#), [306](#), or [307](#) may be used for any purpose other than the purpose for which it was supplied unless such establishment or person has consented (as determined under regulations of the Secretary) to its use for such other purpose; and in the case of information obtained in the course of health statistical or epidemiological activities under section [304](#) or [306](#), such information may not be published or released in other form if the particular establishment or person supplying the information or described in it is identifiable unless such establishment or person has consented (as determined under regulations of the Secretary) to its publication or release in other form.”

Certificates of Confidentiality - (Public Health Service Act, §301(d), 42 USC §241d)

Under section 301(d) of the Public Health Service Act, CDC can provide a certificate of confidentiality to a research project to protect the privacy of individual participants. Researchers who are authorized to protect the privacy of such individuals may not be compelled in any federal, state, or local civil, criminal, administrative, legislative, or other proceedings to identify such individuals, without the individual's consent.

The full text of Section 301(d) of the Public Health Service Act follows:

“The Secretary may authorize persons engaged in biomedical, behavioral, clinical, or other research (including research on mental health, including research on the use and effect of alcohol and other psychoactive drugs) to protect the privacy of individuals who are the subject of such research by withholding from all persons not connected with the conduct of such research the names or other identifying characteristics of such individuals. Persons so authorized to protect the privacy of such individuals may not be compelled in any Federal, State, or local civil, criminal, administrative, legislative, or other proceedings to identify such individuals.”

Applying for Confidentiality Protections

Investigator(s) formally apply for confidentiality protections if they believe such protection is necessary to achieve the project objectives and to obtain valid information of a sensitive nature. The detailed instructions and application forms for obtaining **Confidentiality Assurances (308(d))** and **Certificates of Confidentiality (301(d))** can be obtained from the CDC Management Analysis and Service Office (MASO) website at <http://intranet.cdc.gov/maso/confidentiality/confass.htm> or by contacting the CDC Confidentiality Officer, at 404-498-1506.

FOIA Request

The CDC FOIA staff, Office of Communication, is the focal point for all CDC FOIA requests. The FOIA Officer, Office of Communication (OC), is the sole official with delegated authority to release or deny CDC records. FOIA requests received by a CDC CIO should be sent immediately to the CDC FOIA Officer, Office of Communication (OC), MS-D54, to be logged in and processed. For more information about FOIA contact the CDC FOIA Officer at 404-639-7272.

Table BI: Summary of FOIA, the Privacy Act, 308d, and 301d

Freedom of Information Act	• Obligates federal agencies to disclose certain information upon a written request • An agency may withhold portion of records under 9 exemptions
Privacy Act	• Protects identifiable records held by Federal agencies from improper disclosures • Protects some identifiable records held by contractors of a federal agency • Permits disclosures without consent under 12 exemptions
308(d) Confidentiality Assurance	• Rigorously protects individuals' privacy in research and nonresearch projects • Rigorously protects institutions in research and nonresearch projects
301(d) Certificate of Confidentiality	• Rigorously protects individuals' privacy in research projects

The above laws can be found at <http://www4.law.cornell.edu/uscode/>.

Table B2: Applicability of FOIA, the Privacy Act, 308d, and 301d

	Contracts	Grants	Cooperative Agreements
Privacy Act Applies to all records held at CDC in a “system of records.”	Applicable If the contract calls for a new system of records or extensive additional data that would require establishing a new system. Not applicable If the contractor is adding to his/her already established record system.	Not applicable	Not applicable
Freedom of Information Act Applies to all records held at CDC	Applicable if the records are held at CDC		
308d – Confidentiality Assurance	CDC uses for contracts		
301d – Certificate of Confidentiality		CDC uses for grants and cooperative agreements	

10. Supplemental Reading List

Privacy Protection, General

Gostin LO, Hodge JG, Valdiserri RO. Informational privacy and the public's health: The Model State Public Health Privacy Act. *Am J Public Health*. 2001;91(9):1388-92.

Federal Committee on Statistical Methodology, Confidentiality and Data Access Committee. *Confidentiality and Data Access Issues Among Federal Agencies*. Washington DC: Statistical Policy Office, Office of Management and Budget; 2001. Available at <<http://www.fcsm.gov/cdac/brochur10.pdf>>.

O'Brien DG, Yasnoff WA. Privacy, confidentiality and security in information systems of state health agencies. *American Journal of Preventive Medicine* 1999;16(4):351-8.

Sweeney L. Weaving technology and policy together to maintain confidentiality. *Journal of Law, Medicine & Ethics* 1997;25(2&3):98-110.

Horlick GA. Confidentiality. In: Task Force for Child Survival and Development All Kids Count Program, CDC National Immunization Program. *Community Immunization Registries Manual*. Atlanta: CDC; 2000. Available at <<http://www.cdc.gov/nip/registry/dl/cirman2.pdf>>.

Gostin LO, Hodge JG. *Model State Public Health Privacy Act*. Product of Model State Public Health Privacy Project, sponsored by Centers for Disease Control and Prevention (CDC), Council of State and Territorial Epidemiologists (CSTE), Association of State and Territorial Health Officials (ASTHO), and National Conference of State Legislatures (NCSL). Washington DC: Georgetown University Law Center; 1999. Available at <<http://www.critpath.org/msphpa/privacy.htm>>.

Alpert SA. Health care information: Access, confidentiality, and good practice. In: Goodman KW, editor. *Ethics, Computing, and Medicine: Informatics and the Transformation of Health Care*. Cambridge: Cambridge University Press; 1998. p. 75-101.

National Research Council, Committee on Maintaining Privacy and Security in Health Care Applications of the National Information Infrastructure. *For the Record: Protecting Electronic Health Information*. Washington DC: National Academy Press, 1997. Available at <<http://www.nap.edu/books/0309056977/html/index.html>>.

Gostin LO, Lazzarini Z, Neslund VS, Osterholm MT. The Public Health Infrastructure: A national review of the law on health information privacy. *JAMA* 1996;275(24):1921-7. Full final report from Georgetown/Johns Hopkins Program on Law and Public Health "Legislative Survey of State Confidentiality Laws, with Specific Emphasis on HIV and Immunization" available at <http://epic.org/privacy/medical/cdc_survey.html>.

Cox LH. Protecting confidentiality in small population health and environmental statistics. *Statistics in Medicine* 1996;15(17-18):1895-905.

Fienberg SE. Sharing statistical data in the biomedical and health sciences: Ethical, institutional, legal and professional dimensions. *Annual Review of Public Health* 1994;15:1-18.

Office of Technology Assessment. *Protecting Privacy in Computerized Medical Information*. Washington DC: U.S. Congress; 1993. Report No. OTA-TCT-576.

McLaughlin CC. Confidentiality protection in publicly released central cancer registry data. *Journal of Registry Management* 2002;29(3):84-88.

Disclosure limitation methods

Armstrong MP, Rushton G, Zimmerman DL. Geographically masking health data to preserve confidentiality. *Statistics in Medicine* 1999;18:497-525.

DeWaal AG, Willenborg LCRJ. Optimal local suppression in microdata. *Journal of Official Statistics* 1998;14(4):421-35. Available at <<http://www.jos.nu/Contents/issue.asp?vol=14&no=4>>.

Fienberg SE, Makov UE, Steele RJ. Disclosure limitation using perturbation and related methods for categorical data. *Journal of Official Statistics* 1998;14(4):485-502. Available at <<http://www.jos.nu/Contents/issue.asp?vol=14&no=4>>.

Hundepool AJ, Willenborg LCRJ. ARGUS: Software for Statistical Disclosure Control. In: Federal Committee on Statistical Methodology. *Record Linkage Techniques – 1997: Proceedings of an international workshop and exposition*. Washington DC: Statistical Policy Office, Office of Management and Budget; 1997:142-149. Available at <<http://www.fcsm.gov/working-papers/hundepool.pdf>>.

Sweeney L. Computational Disclosure Control for Medical Microdata: Datafly System. In: Federal Committee on Statistical Methodology. *Record Linkage Techniques – 1997: Proceedings of an international workshop and exposition*. Washington DC: Statistical Policy Office, Office of Management and Budget; 1997:442-453. Available at <<http://www.fcsm.gov/working-papers/latanyas.pdf>>

Federal Committee on Statistical Methodology, Subcommittee on Disclosure Limitation Methodology. *Statistical Policy Working Paper 22 – Report on Statistical Disclosure Limitation Methodology*. Washington DC: Statistical Policy Office, Office of Management and Budget; 1994. NTIS Document No. PB94-165305. Available at <<http://www.fcsm.gov/working-papers/wp22.html>>.

Disclosure risk assessment methodology

Federal Committee on Statistical Methodology, Interagency Confidentiality and Data Access Group. *Checklist on Disclosure Potential of Proposed Data Releases*. Washington DC: Statistical Policy Office, Office of Management and Budget; 1999. Available at <http://www.fcsm.gov/docs/checklist_799.doc>.

Fienberg SE, Makov UE. Confidentiality, uniqueness and disclosure limitation for categorical data. *Journal of Official Statistics* 1998;14(4):385-97. Available at <<http://www.jos.nu/Contents/issue.asp?vol=14&no=4>>.

Samuels SM. A Bayesian species-sampling-inspired approach to the uniques problem in microdata disclosure risk assessment. *Journal of Official Statistics* 1998;14(4):373-83. Available at <<http://www.jos.nu/Contents/issue.asp?vol=14&no=4>>.

Skinner CJ, Holmes. Estimating the re-identification risk per record in microdata. *Journal of Official Statistics* 1998;14(4):361-72. Available at <<http://www.jos.nu/Contents/issue.asp?vol=14&no=4>>.

11. References

-
- ¹ Koo D, Wetterhall SF. History and current status of the National Notifiable Diseases Surveillance System. *J Public Health Management Practice*. 1996;2(4):4-10.
- ² Campbell EG, Clarridge BR, Gokhale M, Birenbaum L, Hilgartner S, Holtzman NA, Blumenthal D. Data withholding in academic genetics: Evidence from a national survey. *JAMA*. 2002;287:473-480.
- ³ Doyle P, Lane JJ, Theeuwes JJ, Zayatz LV. *Confidentiality, Disclosure, and Data Access: Theory and Practical Applications for Statistical Agencies*. Amsterdam, the Netherlands: Elsevier Science, 2001.
- ⁴ National Research Council and Social Research Council. *Private Lives and Public Policies: Confidentiality and Accessibility of Government Statistics*. 1993 Washington D.C.; National Academy Press.
- ⁵ Confidentiality and Data Access Committee, Federal Committee on Statistical Methodology. *Confidentiality and Data Access Issues Among Federal Agencies*; November 2001. Accessible on the Internet at: <http://www.fcsm.gov/cdac/brochur10.pdf>
- ⁶ Federal Committee on Statistical Methodology, Confidentiality and Data Access Committee. Checklist on Disclosure Potential of Proposed Data Releases. July 1999. URL: <http://www.fcsm.gov/committees/cdac/index.html>.
- ⁷ DHHS. CDC Confidentiality. February 1984. Available by contacting the CDC Confidentiality and Privacy Officer, in the Office of the Director, Management Analysis and Services Organization (contact information available at this URL: <http://intranet.cdc.gov/maso/home.htm>).
- ⁸ DHHS. *NCHS Staff Manual on Confidentiality*, dated 1997, available on the Intranet at: < <http://inside.nchs.cdc.gov/frames.htm> > or by contacting the NCHS Confidentiality Officer.
- ⁹ CDC, Excellence in Science sub-committee on Releasing and Sharing Data. *CDC/ATSDR Policy on Releasing and Sharing Data* (currently in the process of being developed).
- ¹⁰ Doyle P, Lane JJ, Theeuwes JJ, Zayatz LV. *Confidentiality, Disclosure, and Data Access: Theory and Practical Applications for Statistical Agencies*. Amsterdam, Netherlands: Elsevier; 2001:4.
- ¹¹ Subcommittee on Disclosure Limitation Methodology, Federal Committee on Statistical Methodology. *Statistical Working Paper 22 Report on Statistical Disclosure*

Methodology, Section B.2. Tables and Microdata (p 3). Washington, DC: Office of Management and Budget, Office of Information and Regulatory Affairs, Statistical Policy Office. May 1994. <http://www.fcsm.gov/working-papers/wp22.html>.

- ¹² Dunne T. Issues in the Establishment and Management of Secure Research Sites. In: Doyle P, Lane JJ, Theeuwes JJ, Zayatz LV. *Confidentiality, Disclosure, and Data Access: Theory and Practical Applications for Statistical Agencies*. Amsterdam, Netherlands: Elsevier; 2001:297-314.
- ¹³ Seastrom MM. Licensing. In: Doyle P, Lane JJ, Theeuwes JJ, Zayatz LV. *Confidentiality, Disclosure, and Data Access: Theory and Practical Applications for Statistical Agencies*. Amsterdam, Netherlands: Elsevier; 2001:279-296.
- ¹⁴ DHHS. Agency for Healthcare Research and Quality, Healthcare Cost and Utilization Project interactive query website. <http://www.ahrq.gov/data/hcup/hcupnet.htm>
- ¹⁵ Land G. Missouri Department of Health and Senior Services—Confidentiality Data Release Rules. Presented at the 2002 CDC Assessment Initiative and National Association for Public Health Statistics and Information Systems. <http://www.cdc.gov/epo/dphsi/AI/confiles/day1/Land1.ppt>
- ¹⁶ CDC. NCHS Policy on Micro-data Dissemination <http://www.cdc.gov/nchs/about/policy/policy.htm>.
- ¹⁷ CDC Information Council. *Public Health Information Network Functions and Specifications, version 1.1*. July 25, 2002 (this draft document is not available on the Internet, but is related to document on the CDC Information Council web site titled: *Public Health IT Functions for Emergency Preparedness and Bioterrorism* at URL: <http://www.cdc.gov/cic/functions-specs/>
- ¹⁸ Department of Health and Human Services. Guidelines for ensuring the quality of information disseminated to the public by the Centers for Disease Control and Prevention and Agency for Toxic Substances and Disease Registry. Accessed November 6, 2002 at URL: <http://www.hhs.gov/infoquality/cdcinfo2.htm>.
- ¹⁹ Subcommittee on Disclosure Limitation Methodology, Federal Committee on Statistical Methodology. *Statistical Working Paper 22 Report on Statistical Disclosure Methodology*. Washington, DC: Office of Management and Budget, Office of Information and Regulatory Affairs, Statistical Policy Office. May 1994. <http://www.fcsm.gov/working-papers/wp22.html>.
- ²⁰ Interagency Confidentiality and Data Access Committee, Federal Committee on Statistical Methodology. Checklist on Disclosure Potential of Proposed Data Releases; 1999. Washington, DC: Office of Management and Budget, Office of Information and Regulatory Affairs, Statistical Policy Office. <<http://www.fcsm.gov/cdac/>>

-
- ²¹ DHHS, Office of Civil Rights. Health Insurance Portability and Accountability Act of 1996 and Privacy Rule. < <http://www.hhs.gov/ocr/hipaa/> >.
- ²² Institute of Medicine, Committee on the Role of Institutional Review Boards in Health Services Research Data Privacy Protection, Division of Health Care Services. *Protecting Data Privacy in Health Services Research*. Washington DC:National Academy Press. 2000.
- ²³ GAO. Record Linkage and Privacy: Issues in Creating New Federal Research and Statistical Information. April 2001. No. GAO-01-126SP.
- ²⁴ Federal Committee on Statistical Methodology, Confidentiality and Data Access Committee. *Identifiability in Microdata Files*. <http://www.fcsm.gov/committees/cdac/>.
- ²⁵ CDC, Health Information and Surveillance Systems Board Confidentiality Group. *CDC Confidentiality Policies and Procedures Drafted by the HISSB Confidentiality Work Group for Confidentiality Section of J. Reid Draft of HISSB Security, Confidentiality and Data Access Program*.
- ²⁶ U.S. Department of Justice, Office of Information and Privacy. *Freedom of Information Act Guide and Privacy Act Overview*, May 2000. See URL: http://www.usdoj.gov/foia/04_3.html and <http://www.usdoj.gov/foia/foiastat.htm>
- ²⁷ O'Brien DG, Yasnoff WA. Privacy, confidentiality and security in information systems of state health agencies. *American Journal of Preventive Medicine* 1999;16(4):351-8.